KR20190010036A - Novel Lactobacillus plantarum K118 with Antioxidant and GABA-producing ability, composition comprising a fermented product of Dendropanax morbifera extract using the same and manufacturing method therof - Google Patents
Novel Lactobacillus plantarum K118 with Antioxidant and GABA-producing ability, composition comprising a fermented product of Dendropanax morbifera extract using the same and manufacturing method therof Download PDFInfo
- Publication number
- KR20190010036A KR20190010036A KR1020170092158A KR20170092158A KR20190010036A KR 20190010036 A KR20190010036 A KR 20190010036A KR 1020170092158 A KR1020170092158 A KR 1020170092158A KR 20170092158 A KR20170092158 A KR 20170092158A KR 20190010036 A KR20190010036 A KR 20190010036A
- Authority
- KR
- South Korea
- Prior art keywords
- strain
- extract
- lactobacillus plantarum
- gaba
- fermented product
- Prior art date
Links
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title claims abstract description 113
- 239000000284 extract Substances 0.000 title claims abstract description 96
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 91
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 91
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 91
- 229960003692 gamma aminobutyric acid Drugs 0.000 title claims abstract description 60
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 21
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 14
- 241000392544 Dendropanax morbifer Species 0.000 title abstract description 6
- 238000000855 fermentation Methods 0.000 claims abstract description 49
- 230000004151 fermentation Effects 0.000 claims abstract description 49
- 230000000694 effects Effects 0.000 claims abstract description 31
- 230000001737 promoting effect Effects 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 241000894006 Bacteria Species 0.000 claims description 17
- 239000007787 solid Substances 0.000 claims description 17
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 11
- 238000011081 inoculation Methods 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 239000003242 anti bacterial agent Substances 0.000 claims description 10
- 229940088710 antibiotic agent Drugs 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 241000196324 Embryophyta Species 0.000 claims description 6
- 102000053187 Glucuronidase Human genes 0.000 claims description 6
- 108010060309 Glucuronidase Proteins 0.000 claims description 6
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 claims description 6
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 claims description 6
- 241000191967 Staphylococcus aureus Species 0.000 claims description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 6
- 229960000723 ampicillin Drugs 0.000 claims description 6
- 229960005091 chloramphenicol Drugs 0.000 claims description 6
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 6
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 claims description 6
- 229960005287 lincomycin Drugs 0.000 claims description 6
- 239000012046 mixed solvent Substances 0.000 claims description 6
- 229960002950 novobiocin Drugs 0.000 claims description 6
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 206010016952 Food poisoning Diseases 0.000 claims description 5
- 208000019331 Foodborne disease Diseases 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
- 229940056360 penicillin g Drugs 0.000 claims description 5
- 229960001225 rifampicin Drugs 0.000 claims description 5
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 5
- 239000004474 valine Substances 0.000 claims description 5
- 101710180684 Beta-hexosaminidase Proteins 0.000 claims description 4
- 101710124976 Beta-hexosaminidase A Proteins 0.000 claims description 4
- 241000186779 Listeria monocytogenes Species 0.000 claims description 4
- 102100030122 Protein O-GlcNAcase Human genes 0.000 claims description 4
- 101710081801 Protein O-GlcNAcase Proteins 0.000 claims description 4
- 101710199095 Putative beta-hexosaminidase Proteins 0.000 claims description 4
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 4
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 4
- 102000006995 beta-Glucosidase Human genes 0.000 claims description 4
- 108010047754 beta-Glucosidase Proteins 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- WQVJHHACXVLGBL-GOVYWFKWSA-N polymyxin B1 Polymers N1C(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)CCCC[C@H](C)CC)CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1CC1=CC=CC=C1 WQVJHHACXVLGBL-GOVYWFKWSA-N 0.000 claims description 3
- 240000008397 Ganoderma lucidum Species 0.000 claims description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 2
- 241001656769 Lilium canadense Species 0.000 claims description 2
- 241000195620 Euglena Species 0.000 claims 2
- 241000218657 Picea Species 0.000 claims 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 claims 1
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 53
- 239000000047 product Substances 0.000 description 51
- 210000004027 cell Anatomy 0.000 description 35
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 19
- 239000002609 medium Substances 0.000 description 18
- 239000012141 concentrate Substances 0.000 description 17
- 230000012010 growth Effects 0.000 description 17
- 235000015097 nutrients Nutrition 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 12
- 239000004310 lactic acid Substances 0.000 description 12
- 235000014655 lactic acid Nutrition 0.000 description 12
- 239000002994 raw material Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 241000186660 Lactobacillus Species 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 235000021109 kimchi Nutrition 0.000 description 10
- 229940039696 lactobacillus Drugs 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 108020004465 16S ribosomal RNA Proteins 0.000 description 8
- 241000223221 Fusarium oxysporum Species 0.000 description 8
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 210000000941 bile Anatomy 0.000 description 6
- 239000000287 crude extract Substances 0.000 description 6
- 239000010779 crude oil Substances 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000002023 wood Substances 0.000 description 6
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 5
- 241000223218 Fusarium Species 0.000 description 5
- 244000184734 Pyrus japonica Species 0.000 description 5
- 230000002292 Radical scavenging effect Effects 0.000 description 5
- 108010059993 Vancomycin Proteins 0.000 description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- -1 glucose Chemical class 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229960003165 vancomycin Drugs 0.000 description 5
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 5
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 235000004347 Perilla Nutrition 0.000 description 4
- 244000124853 Perilla frutescens Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 230000002000 scavenging effect Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 3
- 244000088461 Panicum crus-galli Species 0.000 description 3
- 235000011999 Panicum crusgalli Nutrition 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 230000009603 aerobic growth Effects 0.000 description 3
- 108010028144 alpha-Glucosidases Proteins 0.000 description 3
- 230000009604 anaerobic growth Effects 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 235000014493 Crataegus Nutrition 0.000 description 2
- 241001092040 Crataegus Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000192043 Echinochloa Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 108010093965 Polymyxin B Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229920000024 polymyxin B Polymers 0.000 description 2
- 229960005266 polymyxin b Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- YAHHFDSODKFKOV-NUVHGKSTSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal (2S,3R,4R,5S)-2,3,4,5-tetrahydroxyhexanal Chemical compound C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O YAHHFDSODKFKOV-NUVHGKSTSA-N 0.000 description 1
- ZKIRNCACNZXACZ-MVNLRXSJSA-N (2r,3r,4r,5r)-hexane-1,2,3,4,5,6-hexol;propane-1,2,3-triol Chemical compound OCC(O)CO.OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO ZKIRNCACNZXACZ-MVNLRXSJSA-N 0.000 description 1
- YAHHFDSODKFKOV-ROYBBBCZSA-N (2r,3s,4s,5r)-2,3,4,5,6-pentahydroxyhexanal;(2r,3s,4s,5r)-2,3,4,5-tetrahydroxyhexanal Chemical compound C[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O YAHHFDSODKFKOV-ROYBBBCZSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- VBUYCZFBVCCYFD-JJYYJPOSSA-N 2-dehydro-D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)C(O)=O VBUYCZFBVCCYFD-JJYYJPOSSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 101710195320 Beta-galactosidase 4 Proteins 0.000 description 1
- 101710099633 Beta-glucosidase 4 Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- 108091000069 Cystinyl Aminopeptidase Proteins 0.000 description 1
- 102000030900 Cystinyl aminopeptidase Human genes 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N D-Arabitol Natural products OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241001138420 Fagus crenata Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- HEBKCHPVOIAQTA-IMJSIDKUSA-N L-arabinitol Chemical compound OC[C@H](O)C(O)[C@@H](O)CO HEBKCHPVOIAQTA-IMJSIDKUSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241001233594 Lachnobacterium bovis Species 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- DKXNBNKWCZZMJT-UHFFFAOYSA-N O4-alpha-D-Mannopyranosyl-D-mannose Natural products O=CC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O DKXNBNKWCZZMJT-UHFFFAOYSA-N 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- BTVYFIMKUHNOBZ-ODRIEIDWSA-N Rifamycin S Chemical compound O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-ODRIEIDWSA-N 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- PYMYPHUHKUWMLA-WISUUJSJSA-N aldehydo-L-xylose Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WISUUJSJSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 1
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 1
- 102000019199 alpha-Mannosidase Human genes 0.000 description 1
- 108010012864 alpha-Mannosidase Proteins 0.000 description 1
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- XGPSTANJWFKKMZ-DUMCKRSRSA-N azanium;(3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;chloride Chemical compound [NH4+].[Cl-].OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O XGPSTANJWFKKMZ-DUMCKRSRSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000459 effect on growth Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108010055793 gabase Proteins 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000003898 horticulture Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- DLRVVLDZNNYCBX-ABXHMFFYSA-N melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-ABXHMFFYSA-N 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000001967 plate count agar Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- GSFHMOMWXNDPMM-YMDUGQBDSA-M potassium;(2r,3s,4s)-2,3,4,6-tetrahydroxy-5-oxohexanoate Chemical compound [K+].OCC(=O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O GSFHMOMWXNDPMM-YMDUGQBDSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/038—Gamma-amino butyric acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A23Y2220/67—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
-
- C12R1/25—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
본 발명은 항산화 및 GABA 생성 증진 활성을 갖는 락토바실러스 플란타룸 K118 균주 및 이를 이용한 황칠나무 발효물 및 이의 제조방법에 관한 것으로서, 보다 상세하게는 항산화 및 GABA 생성을 증진하는 우수한 활성을 갖는 신규한 락토바실러스 플란타룸 K118 균주 및 이를 황칠나무 추출물에 접종하여 발효시킴으로써 항산화 및 GABA 함량이 증가된 발효물을 제공하고자 하는 것이다.The present invention relates to a lactobacillus plantarum K118 strain having antioxidative and GABA production promoting activity, a fermented product of the same, and a method for producing the same. More particularly, the present invention relates to a novel fermented product of a novel fermented product Lactobacillus plantarum K118 strain, and a fermented product obtained by inoculating the fermented product with an extract of Fusarium oxysporum species, thereby increasing the antioxidant and GABA contents.
감마아미노부티르산(gamma-amino butyric acid, GABA)은 비단백질 구성 아미노산으로서 뇌에서 신경전달물질로서의 역할뿐 아니라 뇌기능 촉진, 정신안정작용, 혈압저하작용, 이뇨작용, 간 기능 개선 작용, 비만 방지 작용, 알코올대사 촉진작용 및 소취작용 등 매우 다양한 생리기능을 갖는다. 특히 의약품으로 등록되어 뇌졸중 또는 뇌동맥 후유증에 의한 두통, 이명 및 의욕저하 등의 치료에 사용되고 있다.Gamma-amino butyric acid (GABA) is a nonprotein constituent amino acid that acts not only as a neurotransmitter in the brain but also as a brain stimulator, a mental stabilizer, a blood pressure lowering agent, a diuretic agent, , Alcohol metabolism promoting action, and deodorizing action. Especially, it is registered as a medicine and is used for treatment of headache, tinnitus and hypersensitivity due to stroke or cerebral artery sequelae.
GABA는 각종 야채, 과일, 쌀, 콩 등에 널리 분포되어 있는 것으로 알려져 있으나 그 함량이 낮아 생리작용을 나타내지 못하는 단점이 있다. GABA is known to be widely distributed in various vegetables, fruits, rice, beans, etc. However, its content is low and it has a disadvantage that it can not show the physiological function.
황칠나무(Dendropanax morbifera)는 두릅나무과에 속하는 식물로, 만병통치 나무라는 뜻의 학명 덴드로파낙스(Dendro-panax morbifera Nakai)를 가지고 있을 정도로 그 약리학적 효능이 뛰어난 약용식물로, 황칠나무의 수피에서 채취되는 수액인 황칠은 비휘발성분 66.7%, 방향성분 10.8%, 수분 8.1%, 고형분 14.4%로 구성되어 있어, 과거에는 천연도료로 많이 사용되었으나, 최근의 연구 결과에 따르면 당뇨, 고혈압, 혈액순환장애, 간 기능 개선, 항산화, 골다공증, 치주질환, 면역력강화, 신경안정, 항균, 항암 등에 효능이 있다고 보고되고 있다. Dendropanax morbifera is a plant belonging to Araliaceae. It is a medicinal plant with excellent pharmacological efficacy. It has a scientific name Dendro-panax morbifera Nakai , meaning a panacea. In the past, it was used as a natural coating material because it is composed of 66.7% of nonvolatile matter, 10.8% of directional component, 8.1% of moisture, and 14.4% of solid content. However, recent studies have shown that diabetic, hypertensive, , Liver function improvement, antioxidation, osteoporosis, periodontal disease, immunity enhancement, nervous stability, antimicrobial, anticancer and so on.
이러한 황칠나무는 약리효과를 발휘하기 위하여, 유용성분을 추출하여 장기간 복용할 수 있는 방법들이 연구되고 있으나, 황칠나무 추출물은 그 단위 중량당 약리활성이 높지 않고, 인체에 흡수가 느리며, 여러 가지 형태로 제형의 변화가 어렵다는 단점들이 존재한다.In order to exert a pharmacological effect, such a method of extracting a useful component and taking it for a long time has been studied. However, the extract is not high in its pharmacological activity per unit weight, is slow in absorption into the human body, It is difficult to change the formulation.
이러한 연구의 일환으로 황칠나무 잎 분쇄물에 황국균(Aspergillus oryzae)을 접종하고 배양하여 추출한 황칠나무 잎 발효 추출물에 관한 연구가 공지되었으나, 이는 살리실산, 테아플라빈 및 테아플라빈-3-갈레이트 성분의 함량을 증가하기 위한 것이라는 점에서 한계가 있다.As a part of this research, it has been known that fermented extracts of leafy leaves of Aspergillus oryzae were inoculated and cultured in the leaves of the leaves of Tochigi leaves, In order to increase the content of the present invention.
따라서 본 발명자들은 황칠나무 추출물을 이용하여, 항산화 및 GABA 함량을 향상시킬 수 있는 방법을 찾고자 노력한 결과, 신규한 락토바실러스 플란타룸 균주를 분리하고, 이를 이용하여 황칠나무 추출물을 발효하였을 때 항산화 및 GABA 함량이 향상되는 것을 확인함으로써, 이를 통해 GABA 고함유 발효소재 및 그 제조방법을 제공하고자 한다.Therefore, the present inventors have made efforts to find a method of improving antioxidant and GABA content by using the extract of Hwangchujang. As a result, it has been found that a novel Lactobacillus plantarum strain is isolated, By confirming that the GABA content is improved, it is intended to provide a GABA high-content fermentation material and a production method thereof.
본 발명은 상술한 문제점을 해결하기 위해 안출된 것으로서, 본 발명의 목적은 항산화 및 GABA 생성 증진 활성을 갖는 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주(기탁번호 KCCM12015P)를 제공하는 것이다.SUMMARY OF THE INVENTION The present invention has been conceived to solve the above-mentioned problems, and an object of the present invention is to provide Lactobacillus plantarum strain K118 (accession number KCCM12015P) having antioxidative and GABA production promoting activity.
또한, 본 발명의 다른 목적은 황칠나무에 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주(기탁번호 KCCM12015P)를 접종하여 발효시켜 얻은 항산화 및 GABA 함량이 증가한 황칠나무 발효물을 제공하는 것이다.In addition, another object of the present invention is to provide a fermented yellowtail tree having increased antioxidative and GABA contents obtained by fermenting Lactobacillus plantarum K118 strain (accession number KCCM12015P) to a perennial tree.
또한 본 발명의 또 다른 목적은 황칠나무에 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주(기탁번호 KCCM12015P)를 접종하여 발효시키는 것을 특징으로 하는 황칠나무 발효물을 제공하는 것이다.It is still another object of the present invention to provide a fermented product of Fusarium oxysulfurum, which is obtained by inoculating Fusarium oxysporum with a strain of Lactobacillus plantarum K118 (Deposit No. KCCM 12015P).
상술한 목적을 달성하기 위하여, 본 발명은 항산화 및 GABA 생성 증진 활성을 갖는 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주(기탁번호 KCCM12015P)를 제공한다.In order to achieve the above object, the present invention provides a Lactobacillus plantarum K118 strain (Deposit No. KCCM 12015P) having antioxidant and GABA production promoting activity.
상기 균주는 황칠나무 발효용인 것을 특징으로 한다.The strain is characterized in that it is for fermentation of yellow mulberry tree.
상기 균주는 황칠나무 외에 외부 탄소원 없이 배양하는 것을 특징으로 한다.The strain is characterized in that it is cultured in the presence of an external carbon source in addition to Hwangchu.
상기 균주는 내산성 및 내담즙성을 가지는 것을 특징으로 한다.The strain is characterized in that it has acid resistance and biliary cholesterol.
상기 균주는 류신아릴아미다제(Leucine arylamidase), 발린아릴아미다제(Valine arylamidase), N-아세칠-β-글루코스아민니다제(N-acetyl-β-glucosaminidase), β-갈락토시다제(β-galactosidase), α-글루코시다제(α-glucosidase) 및 β-글루코시다제(β-glucosidase)로 이루어진 군으로부터 선택되는 어느 하나이상의 효소에 대해 활성을 가지고 있으나, β-글루쿠로니다제(β-glucuronidase) 효소에 대해서는 활성이 없는 것을 특징으로 한다.The strain may be selected from the group consisting of leucine arylamidase, valine arylamidase, N-acetyl-β-glucosaminidase, β-galactosidase (β -glucosidase, -galactosidase,? -glucosidase and? -glucosidase. However, it is not limited to β-glucuronidase beta-glucuronidase < / RTI > enzyme.
상기 균주는 페니실린-G, 암피실린, 리팜피신, 노보비오신 및 클로람페니콜로 이루어진 군에서 선택되는 어느 하나이상의 항생제에 의해 생육이 저해되고, 린코마이신, 폴리마이신 B 및 반코마이신으로 이루어진 군에서 선택되는 어느 하나이상의 항생제에 대해서는 내성을 가지고 있는 것을 특징으로 한다.Wherein the strain is inhibited from growth by any one or more antibiotics selected from the group consisting of penicillin-G, ampicillin, rifampicin, novobiocin and chloramphenicol, and at least one selected from the group consisting of lincomycin, polymycin B and vancomycin And is resistant to antibiotics.
상기 균주는 식중독균에 대하여 항균활성을 가지고 있는 것을 특징으로 한다.The strain is characterized in that it has antibacterial activity against food poisoning bacteria.
상기 식중독균은 에스케리키아 콜리(Escherichia coli), 살모넬라 타이피머리움(Salmonella Typhimurium), 스테피로코커스 오레우스(Staphylococcus aureus) 및 리스테리아 모노사이토제니스(Listeria monocytogenes)로 이루어진 균으로부터 선택되는 어느 하나 이상인 것을 특징으로 한다.Wherein the food poisoning bacterium is any one or more selected from the group consisting of Escherichia coli , Salmonella Typhimurium , Staphylococcus aureus , and Listeria monocytogenes .
상술한 다른 목적을 달성하기 위하여, 본 발명은 황칠나무에 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주(기탁번호 KCCM12015P)를 접종하여 발효시켜 얻은 항산화 및 GABA 함량이 증가한 황칠나무 발효물을 제공한다.In order to accomplish the above-mentioned other objects, the present invention provides a fermented product of Fusarium oxysporum (Fusarium oxysporum) having increased antioxidative and GABA contents obtained by fermentation by inoculation with Lactobacillus plantarum strain K118 (accession number KCCM 12015P) .
상기 황칠나무는 황칠나무 분쇄물 또는 황칠나무 추출물인 것을 특징으로 한다.The whitish wood is characterized by being a whitened wood pulverized product or an extract of Hokutogi tree.
상기 황칠나무 추출물은 물, 탄소수 1 내지 4의 알코올 또는 이들의 혼합용매의 추출물인 것을 특징으로 한다. The extract is an extract of water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
상기 황칠나무 추출물은 열수 추출물인 것을 특징으로 한다.The extract is a hot-water extract.
상술한 또 다른 목적을 달성하기 위하여, 본 발명은 황칠나무에 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주(기탁번호 KCCM12015P)를 접종하여 발효시키는 것을 특징으로 하는 황칠나무 발효물의 제조방법을 제공한다.According to another aspect of the present invention, there is provided a method for preparing a fermented Yellowlily of Korea, which comprises fermenting a Yellowlake tree by inoculating Lactobacillus plantarum strain K118 (Deposit No. KCCM12015P) .
상기 황칠나무는 황칠나무 분쇄물 또는 황칠나무 추출물인 것을 특징으로 한다.The whitish wood is characterized by being a whitened wood pulverized product or an extract of Hokutogi tree.
상기 황칠나무 추출물은 물, 탄소수 1 내지 4의 알코올 또는 이들의 혼합용매의 추출물인 것을 특징으로 한다. The extract is an extract of water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
상기 황칠나무 추출물은 열수 추출물인 것을 특징으로 한다.The extract is a hot-water extract.
상기 황칠나무 추출물은 총고형분 함량이 0.5~5 중량%이고, pH 2~7이며, 당 농도는 1~5 브릭스(Brixㅀ)인 것을 특징으로 한다.The extract has a total solid content of 0.5 to 5% by weight, a pH of 2 to 7, and a sugar concentration of 1 to 5 Brrix.
상기 황칠나무 추출물은 황칠나무의 잎과 줄기를 8~10 : 1 중량비로 혼합된 것을 특징으로 한다.The extract is a mixture of leaves and stems of Echinochloa crus-galli at 8 to 10: 1 weight ratio.
상기 발효는 25 내지 50 ℃에서 10 내지 96 시간 동안 수행되는 것을 특징으로 한다.Wherein the fermentation is performed at 25 to 50 DEG C for 10 to 96 hours.
상기 발효는 황칠나무 외에 외부 탄소원 없이 배양하는 것을 특징으로 한다.The fermentation is characterized in that it is cultured in the presence of an external carbon source in addition to Hwasungi.
본 발명에 따른 신규한 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주는 황칠나무 추출물을 발효기질로 하여, 황칠나무 추출물에서 항산화 및 GABA 함량을 증가시킬 수 있다. 이를 통해 발효된 황칠나무 발효물은 고농도의 GABA을 포함하고 있으므로 다양한 생리활성 기능이 향상되는 장점을 갖는다.The novel Lactobacillus plantarum K118 strain according to the present invention can increase the antioxidant and GABA content in the extract of Wuchulia chinensis using the Wuchu chrysanthemum extract as a fermentation substrate. This fermented fermented yellowtail has the advantage that various physiological activities are improved because it contains high concentration of GABA.
또한 본 발명에 따른 황칠나무 발효물은 정상세포의 세포사멸을 유도하거나, 세포 독성을 나타내지 않으므로 인체에 대한 안정성이 우수하므로 안전한 의약 또는 식품 첨가물 또는 화장품 원료로 사용될 수 있다.In addition, the fermented product according to the present invention can be used as safe medicines, food additives or cosmetic raw materials since it induces apoptosis of normal cells or does not show cytotoxicity, and thus has excellent stability to human body.
또한, 본 발명의 신규한 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주는 김치로부터 분리된 것으로, 이를 이용하여 제조된 황칠나무 발효물은 기존 화학물질을 통해 제조된 GABA를 고농도로 포함하는 조성물에 비해 독성 및 부작용으로 인한 문제를 저감시킬 수 있다는 장점이 있다.The novel Lactobacillus plantarum K118 strain of the present invention is isolated from kimchi, and the fermented product of Wuchulia japonica prepared by using the Lactobacillus plantarum K118 strain is a composition containing GABA at a high concentration And can reduce problems due to toxicity and side effects.
도 1은 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주의 필로제닉 트리(phylogenic tree)이다.
도 2는 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주에 대해 MRS 액체 배지를 사용하여 34 ℃, 37 ℃ 및 40 ℃에서의 24 시간 동안 생균수(a)와 pH(b)를 측정한 결과이다.
도 3은 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주의 담즙내성을 측정하여 나타낸 결과이다. 이때 총 세 번의 실험을 수행하였고, 이들 데이터는 평균 ± 표준편차로 나타내었다; *p<0.05
도 4는 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주를 다양한 농도의 HCl 용액(pH 2.0, 3.0, 4.0 및 6.4)에 3 시간동안 배양한 후, 생존한 생균수를 측정한 내산성 결과 그래프이다. 이때 총 세 번의 실험을 수행하였고, 이들 데이터는 평균 ± 표준편차로 나타내었다; *p<0.05, **p<0.01, ***p<0.001
도 5는 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주의 HT29 세포에 대한 부착능(adhesion ability)을 측정하여 나타낸 그래프이다. 이때, 총 세 번의 실험을 수행하였고, 데이터는 평균 ± 표준편차로 나타내었다; **p<0.01Figure 1 is a phylogenic tree of Lactobacillus plantarum strain K118.
2 is a result of measuring the number of viable cells (a) and pH (b) for 24 hours at 34 ° C, 37 ° C and 40 ° C using an MRS liquid medium for Lactobacillus plantarum K118 strain .
Fig. 3 shows the result of measuring the bile resistance of Lactobacillus plantarum K118 strain. A total of three experiments were performed at this time, and these data are expressed as mean ± standard deviation; * p < 0.05
FIG. 4 is a graph showing the acid resistance of Lactobacillus plantarum K118 obtained by culturing the strain K118 in various concentrations of HCl solution (pH 2.0, 3.0, 4.0 and 6.4) for 3 hours, and then counting viable cells. A total of three experiments were performed at this time, and these data are expressed as mean ± standard deviation; * p < 0.05, ** p < 0.01, *** p < 0.001
5 is a graph showing the adhesion ability of Lactobacillus plantarum strain K118 to HT29 cells. At this time, a total of three experiments were carried out and the data were expressed as mean ± standard deviation; ** p < 0.01
이에 본 발명자들은 황칠나무 추출물의 관능성 및 기능성을 크게 향상시키는 황칠나무 발효용 신규 균주를 개발하기 위하여 예의 연구 노력한 결과, 본 발명에 따른 황칠나무 발효용 균주, 이를 이용하여 제조된 황칠나무 발효물 및 이의 제조방법을 발견하여 본 발명을 완성하였다.
Accordingly, the inventors of the present invention have made extensive efforts to develop a novel strain for the fermentation of Fusarium oxysporum, which greatly improves the functionality and functionality of the Fusarium oxysporum extract. As a result, it has been found that the strain for fermentation of Fusarium oxysaccharus according to the present invention, And a method for producing the same, and have completed the present invention.
본 발명의 일 측면은 항산화 및 GABA 생성 증진 활성을 갖는 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주(기탁번호 KCCM12015P)에 관한 것이다.One aspect of the present invention relates to a Lactobacillus plantarum K118 strain (Deposit No. KCCM12015P) having antioxidant and GABA production promoting activity.
일반적으로 간균이라고도 부르는 락토바실러스(Lactobacillus) 속에 속하는 균주는 젖산 균주의 일환으로, 젖산균은 글루코오스 등 당류를 분해하여 젖산을 생성하는 세균으로서 흔히 유산균이라고도 한다. Lactobacillus strains belonging to the genus Lactobacillus , commonly referred to as bacilli, are part of lactic acid strains. Lactic acid bacteria are bacteria that produce lactic acid by decomposing saccharides such as glucose, and are often referred to as lactic acid bacteria.
상기 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주는 김치로부터 분리되며, 황칠나무 발효용 균주로, 서열번호 1로 표시되는 16S rDNA를 가지며, 이는 5'에서 3' 방향의 염기서열이다.The Lactobacillus plantarum K118 strain is isolated from kimchi and has a 16S rDNA sequence as shown in SEQ ID NO: 1, which is a 5 'to 3' direction sequence.
상기 락토바실러스 플란타룸(Lactobacillus plantarum K118 균주는 기탁번호는 KCCM12015P이다.The Lactobacillus plantarum K118 strain is deposited at KCCM12015P.
상기 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주는 락토바실러스 플란타룸(Lactobacillus plantarum)과 99% 이상의 상동성을 보일 수 있다.The Lactobacillus plantarum K118 strain may have 99% or more homology with Lactobacillus plantarum .
상기 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주는 황칠나무에 접종하여 발효함으로써, 고농도의 GABA를 포함하는 발효물을 제조할 수 있다는 장점이 있다. 다시 말해 상기 K118 균주는 황칠나무 발효를 통해 항산화 및 GABA 생성 증진 활성을 갖는 균주로, 다른 방법으로 분리된 유산균 또는 락토바실러스 플란타룸에 비해 고농도의 GABA를 함유한 황칠나무 발효물을 제조할 수 있을 뿐만 아니라, 황칠나무 발효물의 관능성과 기능성을 월등히 향상시킬 수 있다.The Lactobacillus plantarum strain K118 is fermented by inoculation on a wild ginseng tree to thereby produce a fermentation product containing a high concentration of GABA. In other words, the K118 strain is a strain having antioxidant activity and GABA production promoting activity through yellowtail millet fermentation, and it is possible to produce a fermented product of Ganoderma lucidum containing GABA at a higher concentration than Lactobacillus isolated from other methods or Lactobacillus plantarum In addition, the sensory and functional properties of the Fusarium oxysporum fungus can be greatly improved.
상기 균주는 김치로부터 분리된 유산균으로, 상기 김치는 일반적인 김치면 특별히 이에 제한되지 않으나, 구체적으로 소금에 절인 김치용 채소 및 양념과 혼합하여 제조된 것일 수 있고, 보다 바람직하게는 제조한 후 20 ℃ 이상의 온도에서 10 일 이상 숙성된 것을 사용하는 것이 바람직하다.The above-mentioned strain is a lactic acid bacterium isolated from kimchi, and the kimchi may be one prepared by mixing with salt-seasoned vegetables and seasoning, but not particularly limited thereto. More preferably, It is preferable to use a product which has been aged for 10 days or more at a temperature.
상기 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주는 황칠나무 외에 외부 탄소원 없이 배양할 수 있는데, 즉 황칠나무를 유일한 영양원으로 하더라도 생육이 잘되며, 항산화 및 GABA 생성 활성도 우수하기 때문에, 고농도의 GABA를 포함하는 황칠나무 발효물을 제조하기 위해서는 황칠나무를 유일한 영양원으로 함유하는 것이 바람직하다.The Lactobacillus plantarum strain K118 can be cultivated in the absence of an external carbon source in addition to Hwangchilmyeong. That is, even if it is used as a sole nutritional source, it grows well and has excellent antioxidant and GABA production activity. Therefore, It is preferable to contain Horticultura as a sole nutrient source to produce the fermented Horticulture.
또한, 황칠나무를 유일한 영양원으로 함으로써, 다른 외부 탄소원을 추가하지 않아도 되기 때문에, 발효기질에 대한 추가 공정 및 비용이 발생하지 않는다는 장점이 있다.In addition, it is advantageous in that it does not require additional external carbon sources and therefore does not require additional processing and costs for the fermentation substrate.
상기 균주는 발효조건이 25 내지 50 ℃에서 10 내지 96 시간 동안 수행될 수 있고, 바람직하게는 34 내지 45 ℃에서 20 내지 30 시간동안 수행될 수 있다. 최종 생성된 발효물의 pH는 4.5 이하인 것을 특징으로 한다. 최적 발효조건은 상술한 조건에 특별히 한정되지 않으나, 발효 온도가 34 ℃ 미만일 경우에는 생장율이 크게 저하되며, 15 ℃에서는 성장이 이루어지지 않는 문제가 있다. 다만 내산성이 우수하므로, 다양한 pH 조건에서 생육할 수 있기 때문에 발효 조건이 단순하므로 비용을 절감할 수 있다.The strain may be fermented at 25 to 50 캜 for 10 to 96 hours, preferably at 34 to 45 캜 for 20 to 30 hours. And the pH of the finally produced fermentation product is 4.5 or less. The optimum fermentation conditions are not particularly limited to the above-mentioned conditions, but when the fermentation temperature is lower than 34 ° C, the growth rate is significantly lowered, and there is a problem that growth is not achieved at 15 ° C. However, since it is excellent in acid resistance, it can be grown under various pH conditions, so that the fermentation conditions are simple and the cost can be reduced.
상기 K118 균주를 통해, 황칠나무를 발효기질로 하여 제조된 황칠나무 발효물은 pH 4.5 이하, 바람직하게는 pH 4-4.5, 라디칼 소거능에 의한 항산화능이 92% 이상인 것으로서, 상기 황칠나무 발효물이 액상일 때 GABA 함량은 황칠나무 발효물 전체 중량 대비 1600 ㎍/㎖ 이상으로 상당히 고농도임을 알 수 있다.Through the strain K118, the Fusarium oxysulfuric acid fermented product prepared from the Fusarium oxysporum fungi as a fermentation substrate has a pH of 4.5 or less, preferably pH 4-4.5, and an antioxidative activity by radical scavenging activity of 92% or more. , The GABA content was significantly higher than 1600 ㎍ / ㎖ in relation to the total weight of the perilla seedlings.
그러므로 상기 황칠나무 발효물의 pH, 항산화능 및 GABA 함량에 의한 수치가 상기 상한치 내지 하한치의 범위 내에서 이루어지게 되면, 기존의 락토바실러스 속에 속하는 다른 균주로부터 발효되는 황칠나무 추출물에 비해 월등히 향상된 기능성을 가지는 것에 해당 할 수 있다. 또한 동속 동종인 것으로서 기존의 다른 식물체나 물질로부터 분리된 락토바실러스 플란타룸에 비해, 황칠나무를 유일한 영양원으로 하는 극한조건에서도 생육활성이 우수하였고, GABA 생성활성도 높았으며, 최종 생성된 발효물의 관능성도 1.5 내지 2 배 뛰어났다.Therefore, if the pH, antioxidant ability and GABA content of the fermented Yellowlard seedlings are in the range of the upper limit value to the lower limit value, it is possible to obtain a fermented ferulic acid fermented product having significantly improved functionality compared to the extract of Yellowlake tree from other strains belonging to the genus Lactobacillus . Compared to Lactobacillus plantarum, which is a homologous strain, the growth activity was excellent and the GABA production activity was high even in the extreme conditions of the only nutrient source, and the sensory properties of the final fermented product 1.5 to 2 times better.
상기 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주는 담즙내성을 가지고, pH 2에서도 안정적으로 GABA 생산 증진 활성을 유지하고 있다는 점에서 내산성이 매우 우수하다 할 것이며, 장 정착능(부착능)도 동종 종속의 다른 균주에 비해 5% 이상 높은 수치를 갖는다. The Lactobacillus plantarum K118 strain is highly resistant to acid because it has bile resistance and stably maintains GABA production promoting activity even at
또한, 상기 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주는 류신아릴아미다제(Leucine arylamidase), 발린아릴아미다제(Valine arylamidase) 및 N-아세칠-β-글루코스아민니다제(N-acetyl-β-glucosaminidase)에 대하여 우수한 효소 활성을 가지고, 그 다음으로 β-갈락토시다제(β-galactosidase), α-글루코시다제(α-glucosidase), β-글루코시다제(β-glucosidase)의 효소 활성도 가지고 있음을 확인하였다. 다만 β-글루쿠로니다제(β-glucuronidase)의 활성은 가지지 않는다. 따라서 본 발명에 따른 K118 균주는 생체에 대한 안정성이 우수함을 확인하였다.The Lactobacillus plantarum strain K118 may also be selected from the group consisting of leucine arylamidase, valine arylamidase and N-acetyl-β-glucanamine -glucosaminidase, and then the enzymatic activity of β-galactosidase, α-glucosidase, and β-glucosidase Respectively. However, it does not have the activity of β-glucuronidase. Therefore, the strain K118 according to the present invention was found to be superior to the living organism.
상기 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주는 페니실린-G, 암피실린, 리팜피신, 노보비오신, 클로람페니콜에 대하여 생육이 억제되고, 린코마이신, 폴리마이신 B, 반코마이신 계열의 항생제에 대해서는 내성을 가지고 있다. The Lactobacillus plantarum K118 strain is resistant to penicillin-G, ampicillin, rifampicin, novobiocin and chloramphenicol, and is resistant to lincomycin, polymycin B and vancomycin antibiotics .
상기 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주는 식중독균에 대하여 높은 항균활성을 가지고 있는데, 구체적으로 에스케리키아 콜리(Escherichia coli), 살모넬라 타이피머리움(Salmonella Typhimurium), 스테피로코커스 오레우스(Staphylococcus aureus), 리스테리아 모노사이토제니스(Listeria monocytogenes)에 대해서 최소 18% 이상, 최대 50%의 항균활성을 갖는다.
The Lactobacillus plantarum strain K118 has a high antimicrobial activity against food poisoning bacteria, specifically Escherichia coli , Salmonella Typhimurium , Staphylococcus aureus Staphylococcus aureus , and Listeria monocytogenes at least 18% and at most 50%.
본 발명의 다른 측면은 황칠나무에 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주(기탁번호 KCCM12015P)를 접종하여 발효시켜 얻은 GABA 함량이 증가한 황칠나무 발효물에 관한 것이다.Another aspect of the present invention relates to a Fagus crenata fermented product having an increased content of GABA obtained by inoculating L. bovis L. with Lactobacillus plantarum strain K118 (accession number KCCM 12015P).
상기 황칠나무 발효물은 황칠나무에 본 발명의 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주를 접종하여 얻은 것이다.The above-described Yellow Fungus tree fermented product is obtained by inoculating Lactobacillus plantarum K118 strain of the present invention into a perennial tree.
상기 황칠나무는 황칠나무 분쇄물 또는 황칠나무 추출물일 수 있다.The perennial plant may be an extract of Echinochloa crataegus or an extract of Echinochloa crus-galli.
상기 황칠나무 추출물은 추출 원재료에 추출 용매를 처리하여 얻은 조추출물뿐만 아니라 조추출물의 가공물도 포함한다. 예를 들어, 황칠나무 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다. 상기 추출물은 상기 조추출물을 추가적으로 분획(fractionation)한 분획물도 포함한다.The Hwigaechuki extract includes not only the crude extract obtained by treating the extraction raw material with the extraction solvent but also the crude extract extract. For example, the extract may be prepared in powder form by an additional process such as vacuum distillation and lyophilization or spray drying. The extract also includes fractions obtained by further fractionating the crude extract.
상기 황칠나무 추출물은 물, 탄소수 1 내지 4의 알코올 또는 이들의 혼합용매의 추출물로서, 추출방법은 특별히 한정할 필요가 없다.The extract is an extract of water, an alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, and the extraction method is not particularly limited.
용매로 물을 사용하는 경우 열수추출이 바람직하다. 예를 들어, 80 내지 105 ℃, 바람직하게는 90 내지 100 ℃의 물에서 0.5 내지 24 시간, 바람직하게는 1 내지 6 시간 추출할 수 있다. 용매로 열수를 사용하지 않더라도, 즉 황칠나무 분말을 냉수 또는 실온의 물에 희석하여 혼합한 희석액에서 황칠나무의 성분이 추출될 수 있다. 냉수 또는 실온의 물을 이용하여 황칠나무 성분을 추출하는 경우 발효와 별도로 추출할 수도 있고, 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주 접종하여 발효되는 과정에서 황칠나무로부터 황칠나무의 성분이 용출되도록 할 수도 있다.When water is used as the solvent, hot water extraction is preferred. For example, at a temperature of 80 to 105 DEG C, preferably 90 to 100 DEG C for 0.5 to 24 hours, preferably 1 to 6 hours. Even if the hot water is not used as a solvent, the components of Hwangryu can be extracted from the diluted solution obtained by diluting the Hwangchu tree powder with cold water or room temperature water. When extracting the woody ingredients using cold water or room temperature water, it may be extracted separately from the fermentation, or may be extracted in the process of fermentation by inoculation with Lactobacillus plantarum K118 strain You may.
상기 탄소수 1 내지 4의 알코올 수용액에 의한 추출물이 사용될 수 있다. 예를 들어, 에탄올, 메탄올, 이소프로판올 등의 알코올 수용액, 바람직하게는 20 내지 80 중량%의 알코올 수용액, 더욱 바람직하게는 50 내지 70 중량%의 알코올 수용액으로 추출한다. 알코올 추출물을 사용하는 경우 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주를 접종하기 전 먼저 알코올 추출물의 알코올을 기화시켜 알코올 함량을 낮춘 농축액 또는 알코올 추출물을 농축 및 건조시킨 후 물에 용해한 후 사용한다. 또한, 본 발명에서 황칠나무 추출물은 넓은 의미로는 황칠나무 분말을 물에 희석한 희석액을 포함한다. An extract of an aqueous solution of an alcohol having 1 to 4 carbon atoms can be used. For example, extraction is carried out with an alcohol aqueous solution such as ethanol, methanol or isopropanol, preferably 20 to 80% by weight aqueous alcohol solution, more preferably 50 to 70% by weight aqueous alcohol solution. When alcohol extracts are used, before inoculation of Lactobacillus plantarum K118 strain, first concentrate the alcohol or alcohol concentrate or alcohol extract which has lowered the alcohol content by evaporating the alcohol of the alcohol extract, and dry it after dissolving in water. In addition, in the present invention, the extract of Hwangchu-myeon is broadly composed of a diluted solution of Hwangchu-myeon powder in water.
상기 황칠나무에 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주를 접종하기 전에 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주의 생육을 증진시키기 위하여 단백질원, 탄수화물원, 비타민 또는 무기질 등의 유산균 영양원을 추가로 혼합할 수 있다. 상기 균주의 영양원은 시중에 판매되는 배지를 이용하거나 또는 필요한 영양원만을 개별적으로 첨가할 수 있다.The hwangchil wood lactic acid nutrient source, such as Lactobacillus Planta room (Lactobacillus plantarum) Lactobacillus Planta room (Lactobacillus plantarum) in order to promote the growth of the K118 strain protein source, a carbohydrate source, vitamins or minerals prior to inoculation the K118 strain Further mixing is possible. The nutrient source of the strain may be a commercially available medium or may be supplemented with only necessary nutrients.
그러나 본 발명에 따른 상기 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주는 황칠나무 외에 외부 탄소원 없이도 즉, 황칠나무를 유일한 영양원으로 하더라도 생육이 활발하며, GABA 생성 활성도 우수하기 때문에, 고농도의 GABA를 포함하는 황칠나무 발효물을 제조하기 위해서는 황칠나무를 유일한 영양원으로 함유하는 것이 바람직하다.However, the Lactobacillus plantarum strain K118 according to the present invention is active even in the presence of an external carbon source, that is, the only nutrient source, in addition to the wild ginseng tree, and the GABA production activity is excellent, so that a high concentration of GABA is contained It is preferable to contain Hwangchujang as a sole nutrient source.
또한, 황칠나무를 유일한 영양원으로 함으로써, 다른 외부 탄소원을 추가하지 않아도 되기 때문에, 발효기질에 대한 추가 공정 및 비용을 절감할 수 있는 효과를 얻을 수 있다.In addition, by making the Hwangchu tree the sole nutritional source, it is possible to obtain an effect of reducing the additional process and cost for the fermentation substrate, since no additional external carbon sources are added.
또한 상기 황칠나무 추출물, 또는 황칠나무 추출물과 상기 균주 영양원의 혼합물은 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주를 접종하기 전에 가열 살균할 수 있다.In addition, the mixture of the above Eustachia japonica extract or a mixture of the Eustachian japonica extract and the above-mentioned strain nutrient can be sterilized by heating before the inoculation of Lactobacillus plantarum K118 strain.
상기 황칠나무 추출물의 고형분 함량은 특별히 한정할 필요는 없으나 추출 후 다른 농축 과정이 없을 경우 0.5 내지 1 중량%이고, 이를 바로 사용할 수도 있고, 농축하여 사용할 수도 있으며, 농축 또는 건조한 후 희석하여 사용할 수도 있다. 상기 황칠나무 추출물을 농축하여 사용할 경우 고형분 함량은 1 내지 10 중량%일 수 있다.The solid content of the extract is not particularly limited, but is 0.5 to 1% by weight when there is no other concentration step after extraction. The extract may be used directly, or may be concentrated, or may be concentrated or dried and then diluted . When the extract is concentrated and used, the solid content may be 1 to 10% by weight.
상기 황칠나무 추출물은 총고형분 함량이 0.5~5 중량%이고, pH 2~7이며, 당 농도는 1~5 브릭스(Brix°)인 것을 사용하는 것이, 균주의 생육활성 및 GABA 생성 증진 활성을 위해 가장 바람직하다.It is preferable that the extract is used in an amount of 0.5 to 5% by weight, a pH of 2 to 7, and a sugar concentration of 1 to 5 Brix to increase the growth activity and GABA production promoting activity of the strain. Most preferred.
상기 발효 조건은 일반적인 유산균 발효와 동일하므로 특별히 한정할 필요는 없으나, 25 내지 50 ℃에서 10 내지 96 시간 수행될 수 있고, 바람직하게는 34 내지 45 ℃에서 20 내지 30 시간동안 수행될 수 있다.The fermentation conditions are the same as those of general lactic acid bacteria fermentation, so that the fermentation conditions are not particularly limited, but they may be performed at 25 to 50 ° C for 10 to 96 hours, preferably 34 to 45 ° C for 20 to 30 hours.
상기 황칠나무 발효물은 균체를 포함하는 발효물일 수 있고, 균체가 제거된 발효물일 수도 있다. 균체가 제거된 발효물은 발효물을 멸균하여 사균체를 포함하게 할 수도 있고, 여과 또는 원심분리를 통해 균체를 제거한 여액 또는 원심분리 상등액일 수 있다. 본 발명의 황칠나무 추출물에 포함된 성분을 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주가 증식하면서 생체 내에서 이용하기 용이한 성분인 GABA로 생물 전환시키거나, 생성하기 때문에, 다양한 생리활성 효과가 상승하였다. 이는 단순한 유산균 자체가 부가되어 얻을 수 있는 효과보다 현저히 상승된 것이다. 상기 황칠나무 발효물은 액상의 발효물을 그 자체로 사용할 수도 있고, 이를 건조하여 분말화할 수도 있다.The Fusarium oxysulfuric acid fermented product may be a fermented product containing cells or a fermented product from which cells have been removed. The fermented product from which the cells have been removed may be sterilized to include dead cells, or may be a filtrate or a centrifuged supernatant from which cells have been removed by filtration or centrifugation. Since the components contained in the extract of the present invention are bioactivated or produced by the Lactobacillus plantarum K118 strain, which is an easily available component in the living body, the various physiological activity effects Respectively. This is remarkably higher than the effect obtained by adding the simple lactic acid bacteria themselves. The fermented product can be used as a liquid fermented product itself, or may be dried and pulverized.
상기 황칠나무 발효물이 액상일 때 GABA 함량은 황칠나무 발효물 전체 중량 대비 1600 ㎍/㎖ 이상인 것으로, 본래 황칠나무가 가지고 있던 GABA 함량보다 1.5 배 이상 증진된 것임을 알 수 있다.
The GABA content of the perilla seedlings was more than 1,600 ㎍ / ㎖ of the total weight of the perilla seedlings, which was 1.5 times more than the GABA content of the perennial seedlings.
본 발명의 또 다른 측면은 황칠나무에 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주(기탁번호 KCCM12015P)를 접종하여 발효시키는 것을 특징으로 하는 황칠나무 발효물의 제조방법에 관한 것이다.Yet another aspect of the present invention relates to a method for producing fermented Yellowlings, which comprises fermenting Yellowlake wood by inoculating Lactobacillus plantarum K118 strain (Deposit No. KCCM12015P).
상기 본 발명의 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주는 상기 균주의 파쇄된 세포벽 분획, 생균, 사균 또는 건조균을 포함하고, 상기 배양액은 상기 균주를 액체 배지에서 배양한 배양액 자체, 상기 배양액을 여과 또는 원심 분리하여 균주를 제거한 여액(원심 분리한 상등액)등을 포함한다.The Lactobacillus plantarum strain K118 of the present invention comprises a crushed cell wall fraction of the strain, a live cell, a dead cell or a dried cell, wherein the culture liquid is a culture medium itself obtained by culturing the strain in a liquid medium, Filtration or centrifugation to remove the strain (centrifuged supernatant), and the like.
상기 배양액은 이를 건조(예컨대 동결건조)한 후 분말화한 것도 포함한다.The culture solution may be dried (e.g., lyophilized) and then powdered.
상기 황칠나무는 황칠나무 분쇄물 또는 황칠나무 추출물일 수 있다.The perennial plant may be an extract of Echinochloa crataegus or an extract of Echinochloa crus-galli.
상기 황칠나무 추출물은 추출 원재료에 추출 용매를 처리하여 얻은 조추출물뿐만 아니라 조추출물의 가공물도 포함한다. 예를 들어, 황칠나무 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다. 상기 추출물은 상기 조추출물을 추가적으로 분획(fractionation)한 분획물도 포함한다.The Hwigaechuki extract includes not only the crude extract obtained by treating the extraction raw material with the extraction solvent but also the crude extract extract. For example, the extract may be prepared in powder form by an additional process such as vacuum distillation and lyophilization or spray drying. The extract also includes fractions obtained by further fractionating the crude extract.
상기 황칠나무 추출물은 물, 탄소수 1 내지 4의 알코올 또는 이들의 혼합용매의 추출물로서, 추출방법은 특별히 한정할 필요가 없다.The extract is an extract of water, an alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, and the extraction method is not particularly limited.
용매로 물을 사용하는 경우 열수추출이 바람직하다. 예를 들어, 80 내지 105 ℃, 바람직하게는 90 내지 100 ℃의 물에서 0.5 내지 24 시간, 바람직하게는 1 내지 6 시간 추출할 수 있다. 용매로 열수를 사용하지 않더라도, 즉 황칠나무 분말을 냉수 또는 실온의 물에 희석하여 혼합한 희석액에서 황칠나무의 성분이 추출될 수 있다. 냉수 또는 실온의 물을 이용하여 황칠나무 성분을 추출하는 경우 발효와 별도로 추출할 수도 있고, 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주 접종하여 발효되는 과정에서 황칠나무로부터 황칠나무의 성분이 용출되도록 할 수도 있다.When water is used as the solvent, hot water extraction is preferred. For example, at a temperature of 80 to 105 DEG C, preferably 90 to 100 DEG C for 0.5 to 24 hours, preferably 1 to 6 hours. Even if the hot water is not used as a solvent, the components of Hwangryu can be extracted from the diluted solution obtained by diluting the Hwangchu tree powder with cold water or room temperature water. When extracting the woody ingredients using cold water or room temperature water, it may be extracted separately from the fermentation, or may be extracted in the process of fermentation by inoculation with Lactobacillus plantarum K118 strain You may.
상기 탄소수 1 내지 4의 알코올 수용액에 의한 추출물이 사용될 수 있다. 예를 들어, 에탄올, 메탄올, 이소프로판올 등의 알코올 수용액, 바람직하게는 20 내지 80 중량%의 알코올 수용액, 더욱 바람직하게는 50 내지 70 중량%의 알코올 수용액으로 추출한다. 알코올 추출물을 사용하는 경우 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주를 접종하기 전 먼저 알코올 추출물의 알코올을 기화시켜 알코올 함량을 낮춘 농축액 또는 알코올 추출물을 농축 및 건조시킨 후 물에 용해한 후 사용한다. 또한, 본 발명에서 황칠나무 추출물은 넓은 의미로는 황칠나무 분말을 물에 희석한 희석액을 포함한다. An extract of an aqueous solution of an alcohol having 1 to 4 carbon atoms can be used. For example, extraction is carried out with an alcohol aqueous solution such as ethanol, methanol or isopropanol, preferably 20 to 80% by weight aqueous alcohol solution, more preferably 50 to 70% by weight aqueous alcohol solution. When alcohol extracts are used, before inoculation of Lactobacillus plantarum K118 strain, first concentrate the alcohol or alcohol concentrate or alcohol extract which has lowered the alcohol content by evaporating the alcohol of the alcohol extract, and dry it after dissolving in water. In addition, in the present invention, the extract of Hwangchu-myeon is broadly composed of a diluted solution of Hwangchu-myeon powder in water.
허나, 황칠나무 추출물에서 불순물의 혼합 정도와 풍미감의 발현 정도를 고려하였을 때, 열수를 이용하여 추출된 것을 발효기질로 사용하는 것이 가장 바람직하다.However, when the degree of mixture of impurities and the degree of expression of flavor are considered in the extract, the most preferred method is to use the extracted water as a fermentation substrate.
상기 황칠나무 추출물에 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주를 접종하기 전에 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주의 생육을 증진시키기 위하여 단백질원, 탄수화물원, 비타민 또는 무기질 등의 유산균 영양원을 추가로 혼합할 수 있다. 상기 균주의 영양원은 시중에 판매되는 배지를 이용하거나 또는 필요한 영양원만을 개별적으로 첨가할 수 있다.In order to enhance the growth of Lactobacillus plantarum K118 strain before the inoculation of Lactobacillus plantarum K118 strain to the extract, the lactic acid bacteria nutrient source such as protein source, carbohydrate source, Can be further mixed. The nutrient source of the strain may be a commercially available medium or may be supplemented with only necessary nutrients.
그러나 본 발명에 따른 상기 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주는 황칠나무 외에 외부 탄소원 없이도 즉, 황칠나무를 유일한 영양원으로 하더라도 생육이 활발하며, 항산화 및 GABA 생성 활성도 우수하기 때문에, 고농도의 GABA를 포함하는 황칠나무 발효물을 제조하기 위해서는 황칠나무를 유일한 영양원으로 함유하는 것이 바람직하다.However, the Lactobacillus plantarum strain K118 according to the present invention is active even in the absence of an external carbon source, that is, the only nutrient source, and has excellent antioxidative and GABA production activity, so that a high concentration of GABA It is preferable that the nutrient source is contained as a sole nutrient source.
또한, 황칠나무를 유일한 영양원으로 함으로써, 다른 외부 탄소원을 추가하지 않아도 되기 때문에, 발효기질에 대한 추가 공정 및 비용을 절감할 수 있는 효과를 얻을 수 있다.In addition, by making the Hwangchu tree the sole nutritional source, it is possible to obtain an effect of reducing the additional process and cost for the fermentation substrate, since no additional external carbon sources are added.
또한 상기 황칠나무 추출물, 또는 황칠나무 추출물과 상기 균주 영양원의 혼합물은 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주를 접종하기 전에 가열 살균할 수 있다.In addition, the mixture of the above Eustachia japonica extract or a mixture of the Eustachian japonica extract and the above-mentioned strain nutrient can be sterilized by heating before the inoculation of Lactobacillus plantarum K118 strain.
상기 황칠나무 추출물의 고형분 함량은 특별히 한정할 필요는 없으나 추출 후 다른 농축 과정이 없을 경우 0.5 내지 1 중량%이고, 이를 바로 사용할 수도 있고, 농축하여 사용할 수도 있으며, 농축 또는 건조한 후 희석하여 사용할 수도 있다. 상기 황칠나무 추출물을 농축하여 사용할 경우 고형분 함량은 1 내지 10 중량%일 수 있다.The solid content of the extract is not particularly limited, but is 0.5 to 1% by weight when there is no other concentration step after extraction. The extract may be used directly, or may be concentrated, or may be concentrated or dried and then diluted . When the extract is concentrated and used, the solid content may be 1 to 10% by weight.
상기 황칠나무 추출물의 성분은 추출하고자 하는 황칠나무 부위에 따라 달라질 수 있으며, 일예로 잎, 줄기, 뿌리, 열매로 이루어진 군으로부터 선택되는 어느 하나 이상일 수 있으나, 황칠나무 추출물의 발효과정에서 불필요한 성분이 혼합되는 것을 방지하기 위하여, 상기 황칠나무 추출물은 황칠나무 잎과 줄기의 혼합물을 원료로 사용하는 것이 가장 바람직하다.The components of the extract are selected from the group consisting of leaves, roots, roots, and fruits. However, the components of the extract are not required in the fermentation process of the extract. In order to prevent mixing, it is most preferable to use a mixture of the leaf and stem of the Hwigae-gil tree as a raw material.
바람직하게 본 발명에서는 황칠나무의 잎과 줄기를 8~10 : 1 중량비로 혼합한 것을 원료로 하여 황칠나무 추출물을 제조하였으며, 상기 범위를 벗어나거나, 뿌리 또는 열매와 같은 다른 부위가 포함될 경우 황칠나무 추출물의 조성이 달라지기 때문에, 발효물에서 GABA 함량이 낮아지는 문제가 발생할 수 있다.Preferably, in the present invention, the extract is prepared from the mixture of leaves and stems of 8% to 10: 1 by weight, and when the leaves are out of the above range or other parts such as roots or fruit are included, Since the composition of the extract varies, the problem of lowering the GABA content in the fermented product may arise.
상기 황칠나무 추출물은 총고형분 함량이 0.5~5 중량%이고, pH 2~7이며, 당 농도는 1~5 브릭스(Brix°)인 것을 사용하는 것이, 균주의 생육활성 및 GABA 생성 증진 활성을 위해 가장 바람직하다.It is preferable that the extract is used in an amount of 0.5 to 5% by weight, a pH of 2 to 7, and a sugar concentration of 1 to 5 Brix to increase the growth activity and GABA production promoting activity of the strain. Most preferred.
또한, 상기 균주를 황칠나무 추출물에 접종하기 전에 영양배지(펩톤, 효모 추출물, 글루코스/증류수)에 접종하고 20 내지 30 ℃에서 18 내지 28 시간 동안 전배양하는 단계;를 더 포함할 수 있고, 상기 전배양액을 상기 황칠나무 추출물에 접종하는 것일 수 있다.In addition, the method may further include the step of inoculating the strain into a nutrient medium (peptone, yeast extract, glucose / distilled water) before inoculating the extract, and pre-culturing the strain at 20 to 30 DEG C for 18 to 28 hours, And then inoculating the pre-culture solution to the above-mentioned Hokutogi extract.
상기 황칠나무 추출물 g 중량당 상기 락토바실러스 플란타룸 K118 균주는 1×104 내지 1×108 CFU 첨가하여 혼합되는 것이 바람직하고, 보다 바람직하게는 상기 황칠나무 추출물 g 중량당 상기 락토바실러스 플란타룸 K118 균주는 1×107 내지 1×108 CFU 첨가하여 혼합하는 것일 수 있다.Preferably, the Lactobacillus plantarum K118 strain is added in an amount of 1 × 10 4 to 1 × 10 8 CFU per g of the extract, and more preferably the Lactobacillus planta / Room K118 The strain may be mixed with 1 x 10 7 to 1 x 10 8 CFU.
상기 발효 조건은 일반적인 유산균 발효와 동일하므로 특별히 한정할 필요는 없으나, 25 내지 50 ℃에서 10 내지 96 시간 수행될 수 있고, 바람직하게는 34 내지 45 ℃에서 20 내지 30 시간동안 수행될 수 있다.The fermentation conditions are the same as those of general lactic acid bacteria fermentation, so that the fermentation conditions are not particularly limited, but they may be performed at 25 to 50 ° C for 10 to 96 hours, preferably 34 to 45 ° C for 20 to 30 hours.
상기 황칠나무 발효물은 균체를 포함하는 발효물일 수 있고, 균체가 제거된 발효물일 수도 있다. 균체가 제거된 발효물은 발효물을 멸균하여 사균체를 포함하게 할 수도 있고, 여과 또는 원심분리를 통해 균체를 제거한 여액 또는 원심분리 상등액일 수 있다. 본 발명의 황칠나무 추출물에 포함된 성분을 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주가 증식하면서 생체 내에서 이용하기 용이한 성분인 GABA로 생물 전환시키거나, 생성하기 때문에, 다양한 생리활성 효과가 상승하였다. 이는 단순한 유산균 자체가 부가되어 얻을 수 있는 효과보다 현저히 상승된 것이다. 상기 황칠나무 발효물은 액상의 발효물을 그 자체로 사용할 수도 있고, 이를 건조하여 분말화할 수도 있다.The Fusarium oxysulfuric acid fermented product may be a fermented product containing cells or a fermented product from which cells have been removed. The fermented product from which the cells have been removed may be sterilized to include dead cells, or may be a filtrate or a centrifuged supernatant from which cells have been removed by filtration or centrifugation. Since the components contained in the extract of the present invention are bioactivated or produced by the Lactobacillus plantarum K118 strain, which is an easily available component in the living body, the various physiological activity effects Respectively. This is remarkably higher than the effect obtained by adding the simple lactic acid bacteria themselves. The fermented product can be used as a liquid fermented product itself, or may be dried and pulverized.
상술한 과정을 통해 제조된 상기 황칠나무 발효물은 상기 황칠나무 발효물이 액상일 때 GABA 함량은 황칠나무 발효물 전체 중량 대비 1600 ㎍/㎖ 이상인 것으로, 본래 황칠나무가 가지고 있던 GABA 함량보다 1.5 배 이상 증진된 것임을 알 수 있다.
The GABA content of the perennial fermented product produced by the above-mentioned process is 1,600 g / ml or more when compared with the total weight of the perilla seedlings. When GABA content is 1.5 times Or more.
이하 본 발명을 바람직한 실시예를 참고로 하여 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 상세히 설명한다. 그러나 본 발명은 여러 가지 상이한 형태로 구현될 수 있으며 여기에서 설명하는 실시예에 한정되는 것은 아니다.
Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings. The present invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.
실험방법Experimental Method
<황칠나무 농축액 제조><Preparation of Yellowtail Tree Concentrate>
열탕기에 황칠 잎과 줄기가 9:1 중량비로 혼합한 후, 이들 고형분 총중량을 1 중량부로 하여, 10 중량부의 물을 첨가한 다음, 100 ℃에서 3 시간 열수 추출하여, 열수추출물을 제조하였다. 상기 열수추출물 중에 포함되어 있는 총고형분은 0.74 중량%였고, pH는 5.1이었다. 10 g of water was added to 1 g of the total solid weight of the mixture, and the mixture was heated at 100 ° C for 3 hours to obtain a hot-water extract. The total solid content contained in the hot water extract was 0.74% by weight and the pH was 5.1.
상기 열수추출물을 발효에 적합한 추출액 상태로 만들기 위해 100 rpm, 50 ℃에서 진공감압농축기(rotavator R-124, Buchi, Switzerland)를 이용하여 농축하여 농축액을 제조하였고, 농축액은 4.0ㅀBrix, pH 5.0이였고, 농축액에 포함되어 있는 총고형분 함량은 4.2 중량%이였다.
The concentrate was concentrated by using a vacuum decompressor (rotavator R-124, Buchi, Switzerland) at 100 rpm and 50 ° C to prepare an extract solution suitable for fermentation. The concentrate was 4.0 ㅀ Brix, pH 5.0 , And the total solid content contained in the concentrate was 4.2 wt%.
실험예 1. 원료로부터 균주 수집 및 분리(1차)Experimental Example 1. Strain Collection and Separation from Raw Materials (Primary)
1) 전통 발효제품에서의 균주 수집 및 분리 1) Collecting and isolating strains in traditional fermented products
김치, 된장 등의 전통 발효제품들로부터 균주를 수집하고 분리하기 위하여, 영양분이 풍부한 액체 배지로 리치 미디어(rich media)인 유산균 전용 MRS(Lactobacillus MRS agar, BD Difco, Sparks, MD, USA)를 기반으로 배지를 제작하였으며, 해당 배지의 매뉴얼에 소개되어 있는 비율을 유지하여 진행하였다.(Lactobacillus MRS agar, BD Difco, Sparks, MD, USA), which is a rich medium, is used as a nutrient-rich liquid medium for collecting and isolating strains from traditional fermentation products such as kimchi, And the ratio of the medium described in the manual was maintained.
다만 MRS 고체배지에는 Bromocresol purple과 sodium azide를 더 포함하여 제조하였고, 상기 MRS 고체배지 각각에 전통 발효제품을 문지른 후, 37 ℃에서 48시간동안 배양한 다음, 노란색 콜로니(colony)중 각기 다른 모양의 콜로니를 선발하여 순수 분리하였다.Bromocresol purple and sodium azide were further added to the MRS solid medium, and the conventional fermented product was rubbed on each of the MRS solid medium, followed by incubation at 37 ° C. for 48 hours. Then, each of the yellow colonies Colonies were selected and purely isolated.
순수분리를 위해, MRS 고체배지에 스트리킹(streaking)하여 해당 콜로니를 분리한 후, 트립티케이스 소이 사면배지(triptic soy agar slant)에 접종하여 37 ℃에서 18 시간동안 배양한 다음, 분리된 균주들을 보관하였다. 그 결과 170종의 전통 발효제품균을 1차적으로 선별하였다.
For pure isolation, the colonies were streaked on MRS solid medium, and the colonies were inoculated on a tryptic soy agar slant and incubated at 37 ° C for 18 hours. Then, Respectively. As a result, 170 kinds of conventional fermentation products were firstly selected.
2) 원유에서의 균주 수집 및 분리2) Strain collection and separation in crude oil
전통 발효제품 대신에 서울우유 중부, 북부, 서부지도소 관할 원유검사소(경기도 및 강원도 일부), 전북 축산시험연구소, 경북 가축위생시험소 및 제주도 축산진흥원에서 지원받은 목장별 원유를 사용한 것을 제외하고는 실험예 1.1)과 균주 수집 및 분리 과정을 모두 동일하게 진행하였다. 그 결과 100 종의 원유분리균을 1차적으로 선별하였다.
Except for traditional fermented products, crude oil was used at each of the farms supported by the crude oil inspection centers (Gyeonggi and Gangwon provinces), Jeonbuk Livestock Research Institute, Gyeongbuk Livestock Hygiene Laboratory, and Cheju Provincial Livestock Promotion Agency in central Seoul, northern and western districts. 1.1) and the process of collecting and isolating strains were performed in the same manner. As a result, 100 kinds of crude oil isolates were firstly selected.
3) 분변에서의 균주 수집 및 분리3) Collecting and isolating strains in feces
전통 발효제품 대신에 배변한 후 3시간이 지나지 않은 분변을 사용한 것을 제외하고는 실험예 1.1)과 균주 수집 및 분리 과정을 모두 동일하게 진행하였다. 그 결과 120 종의 분변분리균을 1차적으로 선별하였다.
Experimental example 1.1) and strain collection and isolation were carried out in the same manner, except that feces instead of conventional fermentation products were used after 3 hours of bowel movement. As a result, 120 kinds of fecal isolates were firstly selected.
실험예 2. 황칠나무 농축액에서 생장하는 균주 선별(2차)Experimental Example 2 Selection of Strains Growing in the Yellow Forest Tree Concentrate (Secondary)
발효능이 있는 균주를 분리하기 위하여 산생성 능력이 요구되므로 황칠나무 농축액에 각 균주들을 각각 배양한 후, 배양액의 pH가 4.5 이하인 균주를 2차적으로 선별하였다.In order to isolate strains with phagocytosis, acid production ability was required. Therefore, each strain was cultivated in an extract of Hwangchulchu and then a strain having a pH value of 4.5 or less was secondly selected.
1차적으로 선별된 균주들을 각각 MRS 액체 배지에 접종하여 37 ℃에서 18 시간동안 배양한 전배양액(109 CFU/㎖)을 황칠나무 농축액에 1% 접종하고 37 ℃에서 24 시간 배양한 후, 황칠나무 발효물을 제조하고, 이의 pH를 측정하여 pH 4.0 이하의 균을 2차 선별한 결과 김치 분리균 13종, 원유 분리균 11 종, 분변 분리균 5 종이 선별되었다. 하기 표 1에 선별된 균주를 원료와 같이 표기하였다.The primary cultures (10 9 CFU / ml) inoculated with MRS liquid medium and incubated at 37 ° C for 18 hours were inoculated 1% to the medium concentration and incubated at 37 ° C for 24 hours. A total of 13 kimchi isolates, 11 crude isolates, and 5 fecal isolates were screened by preparing a fermented tree and measuring the pH of the isolate. The strains selected in Table 1 are indicated as raw materials.
(전통 발효제품균)Kimchi isolate
(Traditional fermentation products)
실험예 3. GABA 생성 증진 활성을 갖는 균주 선발Experimental Example 3. Selection of a strain having GABA production promoting activity
앞선 실험에서 원료로부터 균주를 1차적으로 분리하고, 이를 황칠나무 농축액에 1% 접종하고 24 시간 배양한 후 pH를 측정하여 pH 4.0 이하의 균주를 2차적으로 선별하고, 2차적으로 분리한 균주 각각을 아래 1), 2)에 기술한 DHHP 라디칼 소거능과 GABA 생성능 분석방법을 통해 활성을 비교하였고, 그 결과 가장 활성이 우수한 K118 균주를 최종 선발하였다(표 2).In the previous experiment, the strain was firstly isolated from the raw material, and the strain was inoculated with 1% of the extract in a concentration of yellowtail. After culturing for 24 hours, the pH was measured to secondarily select strains having a pH of 4.0 or less, The results were compared with those of the DHHP radical scavenging ability and the GABA productivity assay described in 1) and 2) below. As a result, the most active K118 strain was finally selected (Table 2).
이때 대조군은 균주를 접종하기 전의 황칠나무 농축액을 시료로 측정한 것이다.At this time, the control group was a sample obtained by measuring the concentration of Hwangchil tree concentrate before the strain was inoculated.
1) DPPH 라디칼 소거능 분석방법1) Analysis method of DPPH radical scavenging ability
측정하고자 하는 시료를 2,2-diphenyl-1-picrylhydrazyl radical(DPPH)과 반응시켜 시료에 의한 라디컬의 소거능을 측정하였다. DPPH 라디칼 소거 활성은 spectrophotometer를 사용하여 515 ㎚에서 흡광도를 측정하였다. The sample was reacted with 2,2-diphenyl-1-picrylhydrazyl radical (DPPH) to measure the radical scavenging activity of the sample. The DPPH radical scavenging activity was measured by using a spectrophotometer at 515 nm.
2) 감마아미노뷰티르산(GABA; γ-AminoButyric Acid) 함량 분석방법2) Analysis method of gamma-aminobutyric acid (GABA) content
GABA 정량분석은 Zhang과 Bown의 방법을 96 well plate에 맞게 수정하여 실시하였다. 에펜돌프 튜브(eppendorf tube)에 시료 0.1 g와 메탄올 400 ㎕를 넣고, 잘 섞은 다음 75 ℃로 예열된 중탕기(water bath)를 사용하여, 약 30 분간 완전히 건조시켰다. 이후 70 mM LaCl3 1 ㎖ 가하고, 13,000ㅧg에서 5 분간 원심 분리한 다음 상등액 700 ㎕을 취하고, 침전물은 버렸다. 상기 상등액 700 ㎕은 에펜돌프 튜브에 취한 후, 여기에 0.1 M KOH 160 ㎕를 첨가하고, 3-5 분간 교반하고 다시 13,000×g에서 5 분간 원심 분리하여, 상등액을 취한다. 이를 희석하여 GABA함량 측정에 이용하였다. GABA함량은 GABase를 이용하는 효소 방법을 사용하였고, 생성되는 NADPH의 양을 ELISA reader를 이용하여 340 ㎚에서 측정하였다.Quantitative analysis of GABA was carried out by adjusting Zhang and Bown 's method to 96 well plate. 0.1 g of the sample and 400 μl of methanol were added to an eppendorf tube, mixed thoroughly, and thoroughly dried for about 30 minutes using a water bath preheated to 75 ° C. Then, 1 ml of 70 mM LaCl 3 was added, centrifuged at 13,000 ㅧ g for 5 minutes, 700 μl of the supernatant was taken, and the precipitate was discarded. 700 μl of the supernatant is taken up in an Eppendorf tube, and then 160 μl of 0.1 M KOH is added thereto. The mixture is stirred for 3-5 minutes, and further centrifuged at 13,000 × g for 5 minutes to obtain a supernatant. This was diluted and used for GABA content measurement. GABA content was determined by using an enzyme method using GABase and the amount of NADPH produced was measured at 340 nm using an ELISA reader.
(ug/mL)GABA generation
(ug / mL)
표 2에 나타난 바와 같이, K118 균주가 DPPH 소거능과 GABA 생성 활성 모두에서 가장 우수한 것을 확인하였다.As shown in Table 2, it was confirmed that K118 strain had the best DPPH scavenging activity and GABA production activity.
동일한 김치를 원료로 분리한 균임에도 K99, K266 등의 균들은 DPPH 소거능이 낮을 뿐만 아니라, 90%에 근접하였다 하더라도 GABA 생성 활성이 1 ㎖ 당 400 내지 700 ㎍의 차이를 나타내고 있음을 확인하였다.Even though the same kimchi was separated into raw materials, K99 and K266 showed low DPPH scavenging ability and showed a difference of 400 ~ 700 ㎍ per 1 ㎖ of GABA production activity even if they were close to 90%.
이러한 차이는 ㎖를 기준으로 측정한 수치에서, 1.5~2 배의 차이에 불과한 것으로 보이나 공정단위에서는 매우 유의미한 정도의 차이이다.
This difference is only a difference of 1.5 to 2 times in the measured value based on ㎖, but it is a very significant difference in the process unit.
실험예 4. K118 균주의 기능성(생리활성) 평가Experimental Example 4. Evaluation of functional (physiological) activity of strain K118
최종 선발된 K118 균주를 황칠나무 농축액에 1% 접종하고 37 ℃에서 24 시간 배양한 황칠나무 발효물을 얻는다. 상기 황칠나무 발효물과 발효전의 기능성(생리활성-항산화/인지기능) 평가하였다.The final selected K118 strain is inoculated 1% in the Hwanyeongkuk concentrate and incubated at 37 ℃ for 24 hours to obtain a yellowtail tree fermented product. The fermented products were evaluated for functionality (bioactivity - antioxidant / cognitive function) before fermentation.
김치분리균 중에서 K118 균주를 제외한 나머지 균주들 중에서 GABA 생성능이 우수한 K99 균주와 K266 균주의 기능성도 평가하여, K118과의 기능성을 비교하였다(표 3).Among the isolates isolated from K118 isolates, the functionalities of K99 and K266 strains with excellent GABA production were also evaluated and compared with those of K118 (Table 3).
1) 활성산소(OH; Hydroxyl radical) 소거활성 분석방법1) Analysis method of active oxygen (OH) scavenging activity
황칠나무 농축액에서 활성산소(OH)의 소거활성 측정은 시험관에 측정하고자 하는 시료 0.2 ㎖와 FeSO4 ·7H2O(10 mM), EDTA(10 mM), 2-deoxyribose(10 mM), 0.1 M 인산완충액(phosphate buffer solution)(pH 7.4) 1.8 ㎖, H2O2(10 mM) 2 ㎖를 가하여, 배양기에서 37 ℃ 조건을 배양하였다. 배양이 완료된 후, 배양액에 1 ㎖의 TCA 용액(2.8%)을 가하여 반응을 중지시키고, 1.0% TBA 용액 1 ㎖를 가하여 100 ℃에서 10 분간 가열한 다음, 급속히 냉각한 후, 이를 532 ㎚에서 흡광도를 측정하였다. In order to measure the scavenging activity of the active oxygen (OH) in the yellowtail concentrate, 0.2 ml of the sample to be measured, 10 mM of FeSO 4 · 7H 2 O, 10 mM of EDTA, 2-deoxyribose (10 mM) 1.8 ml of a phosphate buffer solution (pH 7.4) and 2 ml of H 2 O 2 (10 mM) were added thereto, and the cells were incubated at 37 ° C in an incubator. After completion of the incubation, 1 ml of TCA solution (2.8%) was added to the culture solution to stop the reaction. 1 ml of 1.0% TBA solution was added and the mixture was heated at 100 ° C for 10 minutes. After rapid cooling, Were measured.
2) 과산화물제거효소(SOD; Superoxide dismutase) 활성 분석방법2) Superoxide dismutase (SOD) activity assay method
측정하고자 하는 시료 0.2 ㎖에 Tris-HCl 완충용액(50 mM Tris+10 mM EDTA, pH 8.5) 3 ㎖과 7.2 mM 피로갈산(pyrogallol) 0.2 ㎖를 가하여 25 ℃에서 10분간 반응시킨 후, 1N HCl 0.2 ㎖를 가하여 반응을 정지시키고, 용액 내에 존재하는 산화된 피로갈산의 양을 420 ㎚에서 측정하였다. 이때 SOD 활성은 시료를 첨가한 것과 첨가하지 않은 것을 비교하여 흡광도 감소율을 %로 나타내었다.3 ml of Tris-HCl buffer (50 mM Tris + 10 mM EDTA, pH 8.5) and 0.2 ml of 7.2 mM pyrogallol were added to 0.2 ml of the sample to be measured, and the mixture was incubated at 25 ° C for 10 minutes. Ml was added to stop the reaction, and the amount of oxidized pyrogallic acid present in the solution was measured at 420 nm. At this time, the SOD activity was expressed as% of absorbance reduction by comparing the addition of the sample with the addition of the sample.
표 3에 나타난 바와 같이, 최종 선발된 K118 균주는 다른 균주들에 비해 기능성도 우수한 것으로 확인되었다.
As shown in Table 3, the finally selected K118 strain was found to be more functional than the other strains.
실험예 5. 최종 선발된 K118 균주 동정Experimental Example 5. Identification of the finally selected K118 strain
1) 생리적, 생화학적 특성 분석1) Physiological and biochemical characterization
우선, 최종 선발된 균주 K118의 속과 종을 결정하기 위하여, Gran 염색, 현미경 관찰, 포자생성, 호기적 및 혐기적 성장, catalase 생성, 15℃ 및 45℃에서의 생장, 글루코오스로부터 가스생성, 아르기닌(arginine)으로부터 암모니아(ammonia) 생성 여부 등의 평가를 진행하였고, 이와 더불어 당발효 시험도 실시하여 그 결과를 표 4에 나타내었다. API 당발효 실험 결과는 표 5에 나타내었다.First, in order to determine the genus and species of the finally selected strain K118, gran staining, microscopic observation, sporulation, aerobic and anaerobic growth, catalase production, growth at 15 ° C and 45 ° C, and ammonia production from arginine. The results of the sugar fermentation test were also shown in Table 4. The results of the fermentation experiments per API are shown in Table 5.
표 4에 나타난 바와 같이, 본 발명의 K118 균주는 그람 양성군임을 확인할 수 있었고, 막대 모양(rod)의 간균임을 확인할 수 있었다. 또한 호기적 및 혐기적 생장이 모두 가능하고, 15 ℃에서는 생장하지 못하고, 45 ℃에서 생장이 가능한 것을 확인하였다. As shown in Table 4, the K118 strain of the present invention was confirmed to be a Gram-positive group, and it was confirmed that the K118 strain was a rod-shaped bacterium. Also, aerobic and anaerobic growth were possible, and it was not possible to grow at 15 ℃, and it was confirmed that it could grow at 45 ℃.
2) 16S rDNA 염기서열 분석2) 16S rDNA sequencing
최종 선발된 K118 균주의 동정을 위하여, 16S rDNA 염기서열분석을 실시하였다. 16S rDNA 염기서열 분석은 선발된 K118 균주를 MRS 액체배지에 배양시킨 후, genomic DNA extraction kit(iNtRON Biotechnology, Korea)를 사용하여 DNA를 추출하였다. 추출된 DNA는 1% 아가로스 겔(agarose gel)을 이용하여 확인하였다. 16S rRNA 유전자 부분을 universal primer를 이용하여 PCR을 진행하였다.For the identification of the finally selected K118 strain, 16S rDNA sequencing was performed. For 16S rDNA sequencing, the selected K118 strain was cultured in MRS broth and DNA was extracted using genomic DNA extraction kit (iNtRON Biotechnology, Korea). The extracted DNA was confirmed using 1% agarose gel. The 16S rRNA gene was amplified by PCR using a universal primer.
PCR 조건은 95 ℃에서 1 분간 denaturation, 45 ℃에서 1분간 annealing, 72 ℃에서 1분 30초간 extension으로 30 사이클을 수행하였다.The PCR conditions were 30 cycles of denaturation at 95 ° C for 1 min, annealing at 45 ° C for 1 min, and extension at 72 ° C for 1 min 30 sec.
얻어진 PCR 생성물은 시퀀싱을 위하여 purification kit(iNtRON Biotechnology, Korea)를 이용하여 정제하였다. 움 염기서열은 ABI PRISM 3799 DNA analyzer(Perkin Elmer, U.S.A)를 사용하여 염기서열을 결정하였으며, 이것을 NCBI의 BLAST를 이용하여 GenBank database와 비교하여 K118 균주를 동정하였다.The obtained PCR products were purified using a purification kit (iNtRON Biotechnology, Korea) for sequencing. The nucleotide sequence was determined using ABI PRISM 3799 DNA analyzer (Perkin Elmer, U.S.A), and the K118 strain was identified by comparing it with the GenBank database using NCBI's BLAST.
김치로부터 분리하여 최종 선발된 K118 균주는 16S rDNA 염기서열을 분석한 결과, 락토바실러스 플란타룸(Lactobacillus plantarum)과 99%의 상동성을 나타내었으며, 생리적인 특성으로 항산화능, 산생성능 등의 생리활성 기능성이 우수하다는 점을 확인하였다. 이상의 결과로부터 K118 균주는 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주로 명명하였다.As a result of analysis of 16S rDNA sequence, K118 strain, which was finally isolated from kimchi, showed 99% homology with Lactobacillus plantarum , and it showed physiological characteristics such as antioxidant ability, It was confirmed that the active function was excellent. From the above results, strain K118 was named Lactobacillus plantarum K118 strain.
또한, 본 발명에서는 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주의 16S rDNA가 서열번호 1의 염기서열로 암호화되어 있음을 확인하였고, 이를 한국 미생물 보존센터(KCCM)에 기탁하였으며, KCCM12015P를 부여 받았다.In the present invention, it was confirmed that 16S rDNA of Lactobacillus plantarum strain K118 was encoded by the nucleotide sequence of SEQ ID NO: 1, deposited with the Korean Microorganism Conservation Center (KCCM), and received KCCM12015P .
상기 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주의 필로제닉 트리(phylogenic tree)를 도 1에 나타내었다.
A phylogenic tree of the Lactobacillus plantarum K118 strain is shown in FIG.
기탁기관명 : 한국미생물보존센터(국외)Name of depository: Korea Microorganism Conservation Center (overseas)
수탁번호 : KCCM12015PAccession number: KCCM12015P
수탁일자 : 20170414
Checked on: 20170414
실험예 6. K118 균주의 생장시험Experimental Example 6: Growth test of strain K118
락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주의 생장은 다양한 온도 조건별 생균수 및 pH를 측정하여 시험하였다. 생균수는 MRS 액체배지 150 ㎖에 젖산균을 1 ㎖용 피펫으로 1 방울 접종한 후 34℃, 37 ℃, 40 ℃에서 3 시간 간격으로 24 시간 까지 배양한 각 시료를 0.1% 펩톤용액에 희석하여 BCP plate count agar 평판에서 부어 굳힌 후 35 ℃에서 48 시간 배양하여 계수하였고, 온도 및 시간별로 pH 변화를 측정하였다. 측정 결과는 도 2a, b에 나타내었다. Growth of Lactobacillus plantarum K118 strain was measured by measuring viable cell count and pH at various temperature conditions. The viable cell counts were obtained by inoculating 1 ml of lactic acid bacteria into 150 ml of MRS liquid medium, 1 ml of each pipette, and culturing at 34 ° C, 37 ° C, and 40 ° C for 3 hours at intervals of 24 hours. Each sample was diluted with 0.1% Plate count agar was poured on a plate, hardened, incubated at 35 ° C for 48 hours and counted by pH and temperature. The measurement results are shown in Figs.
도 2는 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주에 대해 MRS 액체 배지를 사용하여 34 ℃, 37 ℃ 및 40 ℃에서의 24 시간 동안 생균수(a)와 pH(b)를 측정한 결과이다. 2 is a result of measuring the number of viable cells (a) and pH (b) for 24 hours at 34 ° C, 37 ° C and 40 ° C using an MRS liquid medium for Lactobacillus plantarum K118 strain .
도 2a, 도 2b에서 볼 수 있는 바와 같이 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주는 생장 최적온도가 34 내지 45 ℃이고, 발효제품의 최적 pH 조건인 pH 4.3 - 4.4에 도달하는데 13 시간 소요되고 있음을 확인하였다.
As can be seen from FIGS. 2A and 2B, the optimum temperature for growth of Lactobacillus plantarum strain K118 is 34 to 45 ° C, and it takes 13 hours to reach the optimum pH condition of the fermentation product, pH 4.3 to 4.4. Respectively.
실험예 7. K118 균주의 담즙내성시험Experimental Example 7. Bile tolerance test of strain K118
담즙내성시험은 길리랜드와 월커의 방법(Gilliland & Walker, J. Dairy Sci., 73, 905, 1990)에 따라 측정하였으며, 측정 결과는 도 3에 나타내었다. The bile tolerance test was performed according to the method of Gilliland and Walker (Gilliland & Walker, J. Dairy Sci., 73, 905, 1990), and the measurement results are shown in FIG.
도 3은 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주의 담즙내성을 측정하여 나타낸 결과이다. 이때 총 세 번의 실험을 수행하였고, 이들 데이터는 평균 ± 표준편차로 나타내었다; *p<0.05Fig. 3 shows the result of measuring the bile resistance of Lactobacillus plantarum K118 strain. A total of three experiments were performed at this time, and these data are expressed as mean ± standard deviation; * p < 0.05
도 3에서 볼 수 있는 바와 같이 7 시간 배양 후 담즙을 첨가하지 않을 때(without oxgall)와 첨가할 때(with oxgall)에 약간 차이를 나타내기 시작하였으나, 미미한 정도이므로 기본적으로 담즙에 대한 내성이 있는 것으로 볼 수 있다.
As can be seen in FIG. 3, after the 7-hour incubation, there was a slight difference between without oxgall and with oxgall, but it was basically insensitive to bile .
실험예 7. K118 균주의 내산성 시험Experimental Example 7. Acid resistance test of strain K118
pH 내성 시험은 클라크 등의 방법(Clark et al., Cultured Dairy Products J., 28(4), 11, 1993)에 따라 측정하였다.The pH tolerance test was carried out according to the method of Clark et al. (Clark et al., Cultured Dairy Products J., 28 (4), 11, 1993).
도 4는 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주를 다양한 농도의 HCl 용액(pH 2.0, 3.0, 4.0 및 6.4)에 3 시간동안 배양한 후, 생존한 생균수를 측정한 내산성 결과 그래프이다. 이때 총 세 번의 실험을 수행하였고, 이들 데이터는 평균 ± 표준편차로 나타내었다; *p<0.05, **p<0.01, ***p<0.001FIG. 4 is a graph showing the acid resistance of Lactobacillus plantarum K118 obtained by culturing the strain K118 in various concentrations of HCl solution (pH 2.0, 3.0, 4.0 and 6.4) for 3 hours, and then counting viable cells. A total of three experiments were performed at this time, and these data are expressed as mean ± standard deviation; * p < 0.05, ** p < 0.01, *** p < 0.001
도 4에 나타난 바와 같이, 염산용액에서 3 시간 후의 락토바실러스 플란타룸(Lactobacillus plantarum) K118의 내성을 비교한 결과, 본 발명의 균주는 pH인 6.4에 비해 강산인 pH 2에서 조차도 생장에 거의 영향을 받지 않음에 따라 매우 강한 내산성을 가짐을 확인할 수 있었다.
As shown in FIG. 4, the resistance of Lactobacillus plantarum K118 after 3 hours in a hydrochloric acid solution was compared. As a result, the strain of the present invention showed almost no effect on growth even at
실험예 8. 대장 상피세포(HT cell)에 대한 K118 균주의 부착능 시험Experimental Example 8. Adhesion test of K118 strain to colon epithelial cells (HT cell)
최종 선별된 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주의 대장 상피세포(HT29-MTX cell)에 대한 부착능을 측정하기 위하여 하기와 같은 실험을 수행하였다.The following experiment was conducted to determine the ability of the finally selected Lactobacillus plantarum strain K118 to coat the colon epithelial cells (HT29-MTX cell).
우선, HT29-MTX 세포를 10%(v/v) heat-inactivated fetal bovine serum과 항생제 혼합물이 첨가된 Dulbecco's modified Eagle's medium(DMEM) 배지에서 배양하였다. 이때 항생제는 최종적으로 50 ㎎/㎖ penicillin, 50 ㎎/㎖ streptomycin, 50 ㎎/㎖ gentamicin 및 1.25 ㎎/㎖ amphotericin B 되도록 하였다.HT29-MTX cells were cultured in Dulbecco's modified Eagle's medium (DMEM) medium supplemented with 10% (v / v) heat-inactivated fetal bovine serum and antibiotic mixture. At this time, the antibiotics were finally made to be 50 mg / ml penicillin, 50 mg / ml streptomycin, 50 mg / ml gentamicin and 1.25 mg / ml amphotericin B, respectively.
HT29-MTX 세포는 30 mm 배양접시에 1 x 105 cells/㎖ 가 되도록 심고 37 ℃에서 14 일 동안 5% CO2 배양기에서 포화상태(약 1 x 107 cells/㎖)로 배양하였다. 모든 실험은 세 번 반복하였다. 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주 배양액은 원심분리로 수거하고 인산완충액으로 두 번 세척한 후 항생제가 들어있지 않은 DMEM에 세균:장 세포가 10:1이 되도록 현탁시켰다. 항생제를 제거하기 위해 HT29-MTX 단일층을 Dulbecco's PBS로 두 번 세척한 후 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주를 첨가하였다. 이 후 37 ℃, CO2 배양기에서 1시간 동안 방치한 후 상등액을 버리고 각 well을 Dulbecco's PBS buffer로 부드럽게 세 번 세척하여 부착되지 않은 세균을 제거하였다. 세포를 4% 고정액(35% formaldehyde 100 ㎖, Na2HPO4 16 g, NaH2PO4·H2O 4 g with distilled water to 1 L)으로 고정하고, 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주는 그람염색하여 광학 현미경으로 관찰하였다. 세포에 부착된 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주 수를 세기 위해서는 먼저 세포와 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주를 0.1% TritonX-100로 배양접시로부터 떼어내고, 이것을 연속 희석하여 100 ㎕ 씩 MRS 고체 배지에 스프레딩 방법으로 접종하였다. 이후 혐기 조건에서 2 일간 배양하여 CFU를 계수하였다. 모든 실험은 세 번 반복하였고, 얻은 데이터는 SPSS 11.0 software forWindows(SPSS Inc., Chicago, IL, USA)로 분석하였다(Gonzalez de los Reyes-Gavilan, Clara et al., 2011. Adhesion of bile-adapted Bifidobacterium strains to the HT29-MTX cell line is modified after sequential gastrointestinal challenge simulated in vitro using human gastric and duodenal juices. Res. Microbiol. 162:514-519; Kainulainena V., J. Reunanena, K. Hiippalaa, S. Guglielmettib, S. Vesterlundc, A. Palvaa and R. Satokaria. 2013. BopA does not have a major role in the adhesion of Bifidobacterium bifidum to intestinal epithelial cells, extracellular matrix proteins, and mucus. Appl. Environ. Microbiol. 79:6989-6997).HT29-MTX cells were seeded in a 30 mm culture dish to 1 x 10 5 cells / ml and cultured at 37 ° C for 14 days in a 5% CO 2 incubator (about 1 × 10 7 cells / ml). All experiments were repeated three times. Lactobacillus plantarum K118 culture broth was collected by centrifugation, washed twice with phosphate buffer, and suspended in DMEM without antibiotics so that the bacterial: intestinal cells were 10: 1. To remove antibiotics, HT29-MTX monolayers were washed twice with Dulbecco's PBS and Lactobacillus plantarum strain K118 was added. After incubation at 37 ° C in a CO 2 incubator for 1 hour, the supernatant was discarded and each well was gently washed three times with Dulbecco's PBS buffer to remove unattached bacteria. Cells were fixed with 4% fixative (35
도 5는 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주의 HT29 세포에 대한 부착능(adhesion ability)를 측정하여 나타낸 그래프이다. 이때, 총 세 번의 실험을 수행하였고, 데이터는 평균 ± 표준편차로 나타내었다; **p<0.015 is a graph showing the adhesion ability of Lactobacillus plantarum strain K118 to HT29 cells. At this time, a total of three experiments were carried out and the data were expressed as mean ± standard deviation; ** p < 0.01
도 5에 나타낸 바와 같이 본 발명의 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주는 장 세포주인 HT29-MTX 세포에 잘 부착되어 있는 것을 확인하였다.
As shown in FIG. 5, the Lactobacillus plantarum strain K118 of the present invention was found to be well adhered to the HT29-MTX cell line.
실시예 9. 효소활성시험Example 9. Enzyme activity test
효소활성시험은 MRS 액체배지에서 37 ℃, 18 시간 동안 배양한 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주를 생리식염수로 희석하여 105 - 106 cfu/㎖ 수준의 시료를 조제한 후, API ZYM 키트(API bioMerieux, France)를 이용하여 37 ℃에서 5 시간 동안 배양한 다음 효소반응을 시켰다. 효소활성은 표준색상표를 비교하여 0-5의 수치로 표시하였고, 결과값은 정리하여 하기 표 6에 나타내었다. 아래 표 6은 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주의 효소활성을 비교한 결과이다.The enzyme activity test was performed by diluting a Lactobacillus plantarum K118 strain cultured in an MRS liquid medium at 37 ° C. for 18 hours with physiological saline to prepare a sample of 10 5 to 10 6 cfu / (API bioMerieux, France) for 5 hours at 37 ° C, followed by enzymatic reaction. The enzyme activity was expressed as 0-5 in comparison with the standard color trademark, and the results are summarized in Table 6 below. Table 6 below shows the results of comparing enzyme activities of Lactobacillus plantarum strain K118.
*: 0에서 5까지 단계별로 표준색이 명시되어 있으며, 0은 음성이고 5는 최대의 강도를 나타낸다. 1은 5 나노몰(nanomoles), 2는 10 나노몰, 3은 20 나노몰, 4는 30 나노몰, 5는 40 나노몰 이상의 효소활성을 나타낸다.*: Standard color is specified in steps from 0 to 5, 0 is negative and 5 is maximum intensity. 1 shows 5 nano moles, 2 has 10 nano moles, 3 has 20 nano moles, 4 has 30 nano moles, and 5 has an enzyme activity of 40 nano moles or more.
상기 표 6에서 볼 수 있는 바와 같이, 락토바실러스 플란타룸(Lactobacillus plantarum) K118은 류신아릴아미다제(Leucine arylamidase), 발린아릴아미다제(Valine arylamidase) 및 N-아세칠-β-글루코스아민니다제(N-acetyl-β-glucosaminidase)에서 효소 활성이 높게 나타났다. As can be seen in Table 6 above, Lactobacillus plantarum K118 was found to inhibit the production of leucine arylamidase, valine arylamidase and N-acetyl-beta -glucosamine (N-acetyl-β-glucosaminidase).
그 다음으로 β-갈락토시다제(β-galactosidase), α-글루코시다제(α-glucosidase), β-글루코시다제(β-glucosidase)에서 효소 활성이 높게 나타났다. 벤조피렌(Benzopyrene)을 발암성 물질로 전환시키는 발암효소인 β-글루쿠로니다제(β-glucuronidase)의 경우에는 효소활성이 없는 것으로 나타나 안전성이 우수한 것을 확인하였다.
The enzyme activity was then found to be high in β-galactosidase, α-glucosidase and β-glucosidase. In the case of β-glucuronidase, a carcinogenic enzyme that converts benzopyrene into a carcinogenic substance, it has been shown that it has no enzyme activity and thus has excellent safety.
실험예 10. K118 균주의 항생제 내성시험Experimental Example 10. Antibiotic resistance test of strain K118
최종 선발된 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주에 대하여 항생제 감수성 시험은 NCCLS(National Committee for Clinical Laboratory Standards)의 디스크 확산법(diffusion method)으로 실시하였다. 사용한 항생제 디스크(BBL Sensi-disc, Becton Dickinson Co., USA)는 아미카신(amikacin, 30 ㎍, AN), 젠타마이신(gentamicin, 10 ㎍, GM), 카나마이신(kanamycin, 30 ㎍, K), 네오마이신(neomycin, 30 ㎍, N), 스트렙토마이신(streptomycin, 10 ㎍, S), 페니실린-G(penicillin-G, 10 ㎍, AM), 옥사실린(Oxacillin, 10 ㎍, AM), 암피실린(ampicillin, 10 ㎍, AM), 바시트라신(Bacitracin, 20 ㎍, AM), 리팜피신(Rifampicin, 10 ㎍, AM), 노보비오신(Novobiocin, 10 ㎍, AM), 린코마이신(lincomycin, 2 ㎍, L), 폴리믹신 B(Polymyxin B, 2 ㎍, L), 클로람페니콜(Chloramphenicol, 2 ㎍, L) 및 반코마이신(Vancomycin, 5 ㎍, L) 등 15종을 사용하였다. 최종 선별된 K118 균주를 Mueller Hinton Broth(MErck, Germany)에 접종하고 37℃에서 5시간 동안 배양한 후 0.5 MacFarland(BioMerieux)의 균액으로 희석한 후 Muller-Hinton agar(Difco)에 도말한 후 30분간 건조시킨 후 15종의 항생제 디스크를 올려놓고 37℃에서 1일간 배양하였다. 각 항생제에 대한 억제환의 크기를 측정하고 CLSI 가이드라인에 의해 내성을 판정하였다.The antibiotic susceptibility test of Lactobacillus plantarum strain K118 was performed by the diffusion method of the National Committee for Clinical Laboratory Standards (NCCLS). Antibiotic discs (BBL Sensi-disc, Becton Dickinson Co., USA) used were amikacin (30 μg, AN), gentamicin (10 μg, GM), kanamycin (10 μg, AM), ampicillin (10 μg, S), neomycin (30 μg, N), streptomycin , 10 μg, AM), bacitracin (20 μg, AM), rifampicin (10 μg, AM), Novobiocin (10 μg, AM), lincomycin ), Polymyxin B (2 ㎍, L), chloramphenicol (2 ㎍, L) and vancomycin (5 ㎍, L) The final selected strain K118 was inoculated into Mueller Hinton Broth (MErck, Germany), incubated at 37 ° C for 5 hours, diluted with 0.5 MacFarland (BioMérieux), and spread on Muller-Hinton agar (Difco) After drying, 15 antibiotic discs were placed and incubated at 37 ° C for 1 day. The size of inhibitory ring for each antibiotic was measured and tolerance was determined by CLSI guideline.
R은 항생제 내성을 가지고 있는 것(억제환 크기 : 0 ㎜), IS는 중간 감수성(intermediate susceptibility)을 가짐(억제환 크기 : 1-5 ㎜); S는 감수성을 나타내고 있음(susceptibility)(억제환 크기 : >5 ㎜)을 표기한 것이다.R has antibiotic resistance (inhibitory ring size: 0 ㎜), IS has intermediate susceptibility (inhibitory ring size: 1-5 ㎜); S indicates susceptibility (inhibition ring size:> 5 mm).
표 7에 나타난 바와 같이, 본 발명에 따른 K118 균주는 항생제 감수성을 조사한 결과, 페니실린-G, 암피실린, 리팜피신, 노보비오신, 클로람페니콜에 대하여 생육이 억제됨을 확인하였고, 린코마이신, 폴리마이신 B, 반코마이신 계열의 항생제에 대하여는 내성을 지니고 있음을 확인하였다.
As shown in Table 7, the strain K118 according to the present invention was found to inhibit the growth of penicillin-G, ampicillin, rifampicin, novobiocin and chloramphenicol as antibiotics susceptibility, and the inhibition of growth of lincomycin, polymacin B, vancomycin And antibiotics of the family.
실험예 11. K118 균주의 항균력 시험Experimental Example 11. Antibacterial Test of K118 Strain
항균력 시험은 길리랜드와 스펙(Gilliland & Speck, J. Food Prot., 40(12), 820, 1977)에 따라 측정하였으며, 측정 결과는 아래 표 8에 나타내었다. 아래 표 8은 MRS 배지에서 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주에 의한 항균활성을 측정한 결과이다. 이때, 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주의 초기 농도(initial count)는 4.93 ± 0.25 × 106 CFU/㎖였고(*), a는 37 ℃에서 6 시간동안 배양한 후, 측정하였음을 의미하는 것이다.The antimicrobial activity test was carried out according to Gilliland & Speck, J. Food Prot., 40 (12), 820, 1977. The measurement results are shown in Table 8 below. Table 8 below shows the results of measurement of antimicrobial activity of Lactobacillus plantarum K118 strain on MRS medium. The initial count of Lactobacillus plantarum K118 strain was 4.93 ± 0.25 × 10 6 CFU / ml (*), and a was measured after incubation at 37 ° C. for 6 hours It means.
상기 표 8에서 볼 수 있는 바와 같이, 본 발명의 락토바실러스 플란타룸(Lactobacillus plantarum) K118은 에스케리키아 콜리(Escherichia coli)에 대해 37.11%의 억제력을 보였고, 살모넬라 타이피머리움(Salmonella Typhimurium)에 대해서는 50%로 향상된 억제력을 나타내었다. 스테피로코커스 오레우스(Staphylococcus aureus)에 대해서는 18.01%로 낮지만 어느 정도 억제력을 나타내고 있음을 확인하였다.
As can be seen in Table 8, the Lactobacillus plantarum K118 of the present invention showed an inhibitory effect on Escherichia coli of 37.11%, Salmonella Typhimurium , And 50%, respectively. And Staphylococcus aureus ( Staphylococcus aureus ) was 18.01%.
실험예 12. 발효기질의 종류에 따른 발효물의 발효특성 확인.EXPERIMENTAL EXAMPLE 12. Confirmation of fermentation characteristics of fermented products according to kinds of fermentation medium.
열탕기에 원료를 혼합한 후, 이들 고형분 총중량을 1 중량부로 하여, 10 중량부의 물을 첨가한 다음, 100 ℃에서 3 시간 열수 추출하여, 열수추출물을 제조하였다. 상기 열수추출물 중에 포함되어 있는 총고형분은 0.74 중량%였고, pH는 5.1이었다. 10 parts by weight of water was added to 1 part by weight of the total solid content of these solid components, and the mixture was subjected to hot water extraction at 100 DEG C for 3 hours to prepare a hot water extract. The total solid content contained in the hot water extract was 0.74% by weight and the pH was 5.1.
상기 열수추출물을 발효에 적합한 추출액 상태로 만들기 위해 100 rpm, 50 ℃에서 진공감압농축기(rotavator R-124, Buchi, Switzerland)를 이용하여 농축하여 농축액을 제조하였다. 상기 원료는 황칠나무 잎만 사용한 것, 황칠나무 줄기만 사용한 것, 황칠나무 잎과 줄기가 각각 7:1의 중량비, 11:1의 중량비, 15:1의 중량비를 갖는 5 가지 황칠나무 농축액을 제조하였다.The concentrate was concentrated using a vacuum decompressor (rotavator R-124, Buchi, Switzerland) at 100 rpm and 50 ° C to obtain an extract solution suitable for fermentation. Five kinds of Bulgogi concentrate having a weight ratio of 7: 1, a weight ratio of 11: 1, and a weight ratio of 15: 1, respectively, were used: .
서로 다른 원료를 통해 제조된 황칠나무 농축액을 발효기질로 사용할 경우, 발효물의 발효특성을 확인하기 위하여, 상기 5 가지의 황칠나무 농축액에 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주를 각각 접종 후, 24 시간째에 발효물에서의 DPPH(%)와 GABA 함량을 비교하여 표 9에 나타내었다. 이때 실시예는 실험예 3에서 K118 균주를 황칠나무 농축액(잎과 줄기의 중량비 9:1) 접종하여 발효시킨 황칠나무 발효액을 측정한 것이다.In order to confirm the fermentation characteristics of the fermented product when the Yellowish chestnut concentrate prepared from different raw materials was used as a fermentation substrate, Lactobacillus plantarum K118 strain was inoculated to each of the above five yellowtail concentrates, The percentage of DPPH (%) and GABA in the fermented product at 24 hours is shown in Table 9. In this example, the K118 strain was inoculated with the Hwanyeongkuk concentrate (weight ratio of leaves and stem of 9: 1) in Experimental Example 3 to measure the fermented broccoli extract.
(ug/mL)GABA generation
(ug / mL)
표 9에 나타난 바와 같이, 본 발명의 황칠나무 발효물은 황칠나무의 잎과 줄기의 중량비가 8-10:1의 범위 내로 혼합되어 제조된 농축액을 사용할 경우, 가장 우수한 GABA 생성 활성과 DPPH(%)를 가진다는 것을 다시금 확인할 수 있었다.As shown in Table 9, when the concentrated fermented product of the present invention was used in a weight ratio of 8: 10: 1, the highest GABA production activity and DPPH (% ).
이는 각 부위에 따라 추출물의 성분이 달라지기 때문에, 이러한 원료의 차이로 인해 균주의 생육활성이나, 활성화되는 영향을 미치게 되고, 결국 최종 생성되는 발효물의 기능성이나 GABA 함량도 달라지게 되는 것을 알 수 있다.Since the components of the extract vary depending on each site, the difference in the raw materials causes the growth and activation of the strain, and thus the functionality and GABA content of the final fermentation product are different from each other .
상기에서는 본 발명의 바람직한 실시예에 대하여 설명하였지만, 본 발명은 이에 한정되는 것은 아니고, 본 발명의 기술 사상 범위 내에서 여러 가지로 변형하여 실시하는 것이 가능하고, 이 또한 첨부된 특허 청구 범위에 속하는 것은 당연하다.
While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed exemplary embodiments, but, on the contrary, is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims. It is natural.
<110> KOREA FOOD RESEARCH INSTITUTE <120> Novel Lactobacillus plantarum K118 with Antioxidant and GABA-producing ability, composition comprising a fermented product of Dendropanax morbifera extract using the same and manufacturing method therof <130> HP7343 <160> 1 <170> KoPatentIn 3.0 <210> 1 <211> 1051 <212> DNA <213> Unknown <220> <223> 16S rDNA of Lactobacillus plantarum K118 <400> 1 gacttcgatg atgctagtgt tggagggttt ccgcccttca gtgctgcagc taacgcatta 60 agcattccgc ctggggagta cggccgcaag gctgaaactc aaaggaattg acgggggccc 120 gcacaagcgg tggagcatgt ggtttaattc gaagctacgc gaagaacctt accaggtctt 180 gacatactat gcaaatctaa gagattagac gttcccttcg gggacatgga tacaggtggt 240 gcatggttgt cgtcagctcg tgtcgtgaga tgttgggtta agtcccgcaa cgagcgcaac 300 ccttattatc agttgccagc attaagttgg gcactctggt gagactgccg gtgacaaacc 360 ggaggaaggt ggggatgacg tcaaatcatc atgcccctta tgacctgggc tacacacgtg 420 ctacaatgga tggtacaacg agttgcgaac tcgcgagagt aagctaatct cttaaagcca 480 ttctcagttc ggattgtagg ctgcaactcg cctacatgaa gtcggaatcg ctagtaatcg 540 cggatcagca tgccgcggtg aatacgttcc cgggccttgt acacaccgcc cgtcacacca 600 tgagagtttg taacacccaa agtcggtggg gtaacctttt aggaaccagc cgcctaaggt 660 gggacagatg attagggtga agtcgtcaaa ggggtaacca aaaaaagtgg caccagggga 720 tctacggggg ttcgcccccg ttatccagaa gttaacaacc ggcttacccg agggttttcc 780 ccctcgttat ctcgcccgtt tttccactag attccagagg gcgtttcctc ctgttcttgt 840 tcgagggaac ctgcttccct atataacgcg ctcaactttc ttctgacgga gaacaagact 900 gtccatcaaa aaatacttgc aaacaagcct gttcggcgct ctaaaattcc ccacccaaag 960 cttccggcac agctattttg gcccctacaa gtgttatctc aggcccctgt ggacagggaa 1020 ctaattcttt cggcggggcg tttggattgg a 1051 <110> KOREA FOOD RESEARCH INSTITUTE <120> Novel Lactobacillus plantarum K118 with Antioxidant and GABA-producing ability, composition comprising a fermented product of Dendropanax morbifera extract using the same and manufacturing method therof <130> HP7343 <160> 1 <170> KoPatentin 3.0 <210> 1 <211> 1051 <212> DNA <213> Unknown <220> <223> 16S rDNA of Lactobacillus plantarum K118 <400> 1 gacttcgatg atgctagtgt tggagggttt ccgcccttca gtgctgcagc taacgcatta 60 agcattccgc ctggggagta cggccgcaag gctgaaactc aaaggaattg acgggggccc 120 gcacaagcgg tggagcatgt ggtttaattc gaagctacgc gaagaacctt accaggtctt 180 gacatactat gcaaatctaa gagattagac gttcccttcg gggacatgga tacaggtggt 240 gcatggttgt cgtcagctcg tgtcgtgaga tgttgggtta agtcccgcaa cgagcgcaac 300 ccttattatc agttgccagc attaagttgg gcactctggt gagactgccg gtgacaaacc 360 ggaggaaggt ggggatgacg tcaaatcatc atgcccctta tgacctgggc tacacacgtg 420 ctacaatgga tggtacaacg agttgcgaac tcgcgagagt aagctaatct cttaaagcca 480 ttctcagttc ggattgtagg ctgcaactcg cctacatgaa gtcggaatcg ctagtaatcg 540 cggatcagca tgccgcggtg aatacgttcc cgggccttgt acacaccgcc cgtcacacca 600 tgagagtttg taacacccaa agtcggtggg gtaacctttt aggaaccagc cgcctaaggt 660 gggacagatg attagggtga agtcgtcaaa ggggtaacca aaaaaagtgg caccagggga 720 tctacggggg ttcgcccccg ttatccagaa gttaacaacc ggcttacccg agggttttcc 780 ccctcgttat ctcgcccgtt tttccactag attccagagg gcgtttcctc ctgttcttgt 840 tcgagggaac ctgcttccct atataacgcg ctcaactttc ttctgacgga gaacaagact 900 gtccatcaaa aaatacttgc aaacaagcct gttcggcgct ctaaaattcc ccacccaaag 960 cttccggcac agctattttg gcccctacaa gtgttatctc aggcccctgt ggacagggaa 1020 ctaattcttt cggcggggcg tttggattgg a 1051
Claims (21)
상기 균주는 황칠나무 발효용인 것을 특징으로 하는 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주.The method according to claim 1,
The strain Lactobacillus plantarum K118 strain is characterized in that it is used for fermentation of yellowtail.
상기 균주는 황칠나무 외에 외부 탄소원 없이 배양하는 것을 특징으로 하는 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주.The method according to claim 1,
A strain of Lactobacillus plantarum K118, wherein the strain is cultured in the absence of an external carbon source in addition to the woodweed.
상기 균주는 내산성 및 내담즙성을 가지는 것을 특징으로 하는 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주.The method according to claim 1,
Wherein the strain has acid-fastness and biliary-bility. Lactobacillus plantarum K118 strain.
상기 균주는 류신아릴아미다제(Leucine arylamidase), 발린아릴아미다제(Valine arylamidase), N-아세칠-β-글루코스아민니다제(N-acetyl-β-glucosaminidase), β-갈락토시다제(β-galactosidase), α-글루코시다제(α-glucosidase) 및 β-글루코시다제(β-glucosidase)로 이루어진 군으로부터 선택되는 어느 하나이상의 효소에 대해 활성을 가지고 있으나, β-글루쿠로니다제(β-glucuronidase) 효소에 대해서는 활성이 없는 것을 특징으로 하는 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주.The method according to claim 1,
The strain may be selected from the group consisting of leucine arylamidase, valine arylamidase, N-acetyl-β-glucosaminidase, β-galactosidase (β -glucosidase, -galactosidase,? -glucosidase and? -glucosidase. However, it is not limited to β-glucuronidase Lactobacillus plantarum K118 strain characterized in that it has no activity against the enzyme β-glucuronidase.
상기 균주는 페니실린-G, 암피실린, 리팜피신, 노보비오신 및 클로람페니콜로 이루어진 군에서 선택되는 어느 하나이상의 항생제에 의해 생육이 저해되고,
린코마이신, 폴리마이신 B 및 반코마이신으로 이루어진 군에서 선택되는 어느 하나이상의 항생제에 대해서는 내성을 가지고 있는 것을 특징으로 하는 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주.The method according to claim 1,
The strain is inhibited by any one or more antibiotics selected from the group consisting of penicillin-G, ampicillin, rifampicin, novobiocin and chloramphenicol,
Lactobacillus plantarum K118 strain characterized in that it is resistant to any one or more antibiotics selected from the group consisting of lincomycin, polymycin B and vancomycin.
상기 균주는 식중독균에 대하여 항균활성을 가지고 있는 것을 특징으로 하는 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주.The method according to claim 1,
The strain Lactobacillus plantarum K118 strain is characterized in that it has antibacterial activity against food poisoning bacteria.
상기 식중독균은 에스케리키아 콜리(Escherichia coli), 살모넬라 타이피머리움(Salmonella Typhimurium), 스테피로코커스 오레우스(Staphylococcus aureus) 및 리스테리아 모노사이토제니스(Listeria monocytogenes)로 이루어진 균으로부터 선택되는 어느 하나 이상인 것을 특징으로 하는 락토바실러스 플란타룸(Lactobacillus plantarum) K118 균주.8. The method of claim 7,
Wherein the food poisoning bacterium is any one or more selected from the group consisting of Escherichia coli , Salmonella Typhimurium , Staphylococcus aureus , and Listeria monocytogenes Lactobacillus plantarum K118 strain characterized.
상기 황칠나무는 황칠나무 분쇄물 또는 황칠나무 추출물인 것을 특징으로 하는 황칠나무 발효물.10. The method of claim 9,
Characterized in that the Hwigae-jinja is an Euglena crush or a Hwigae-jinja extract.
상기 황칠나무 추출물은 물, 탄소수 1 내지 4의 알코올 또는 이들의 혼합용매의 추출물인 것을 특징으로 하는 황칠나무 발효물.11. The method of claim 10,
Wherein the extract is an extract of water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
상기 황칠나무 추출물은 열수 추출물인 것을 특징으로 하는 황칠나무 발효물.11. The method of claim 10,
Wherein the extract is a hydrothermal extract.
상기 황칠나무 발효물이 액상일 때, 상기 황칠나무 발효물에서 GABA 함량은 황칠나무 발효물 전체 중량 대비 1600 내지 2000 ㎍/㎖ 이상인 것을 특징으로 하는 황칠나무 발효물.10. The method of claim 9,
Wherein the GABA content of the perennial fermented product is in the range of 1600 to 2000 g / ml or more based on the total weight of the perennial fermented product.
상기 황칠나무는 황칠나무 분쇄물 또는 황칠나무 추출물인 것을 특징으로 하는 황칠나무 발효물의 제조방법.15. The method of claim 14,
Wherein the Hwigae-jinja is an Euglena crush or a Hwangchu-jaeng extract.
상기 황칠나무 추출물은 물, 탄소수 1 내지 4의 알코올 또는 이들의 혼합용매의 추출물인 것을 특징으로 하는 황칠나무 발효물의 제조방법.16. The method of claim 15,
Wherein the extract is an extract of water, an alcohol having 1 to 4 carbon atoms or a mixed solvent thereof.
상기 황칠나무 추출물은 열수 추출물인 것을 특징으로 하는 황칠나무 발효물의 제조방법.16. The method of claim 15,
Wherein the extract is a hot-water extract.
상기 황칠나무 추출물은 총고형분 함량이 0.5~5 중량%이고, pH 2~7이며, 당 농도는 1~5 브릭스(Brix°)인 것을 특징으로 하는 황칠나무 발효물의 제조방법.16. The method of claim 15,
Wherein the extract has a total solid content of 0.5 to 5% by weight, a pH of 2 to 7, and a sugar concentration of 1 to 5 Brrix.
상기 황칠나무 추출물은 황칠나무의 잎과 줄기를 8~10 : 1 중량비로 혼합된 것을 특징으로 하는 황칠나무 발효물의 제조방법.15. The method of claim 14,
Wherein the extract is a mixture of leaves and stems of a perennial plant of 8 to 10: 1 by weight.
상기 발효는 25 내지 50 ℃에서 10 내지 96 시간 동안 수행되는 것을 특징으로 하는 황칠나무 발효물의 제조방법.15. The method of claim 14,
Wherein the fermentation is carried out at 25 to 50 DEG C for 10 to 96 hours.
상기 발효는 황칠나무 외에 외부 탄소원 없이 배양하는 것을 특징으로 하는 황칠나무 발효물의 제조방법.15. The method of claim 14,
Wherein the fermentation is carried out in the absence of an external carbon source in addition to the woody spruce.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170092158A KR101962291B1 (en) | 2017-07-20 | 2017-07-20 | Novel Lactobacillus plantarum K118 with Antioxidant and GABA-producing ability, composition comprising a fermented product of Dendropanax morbifera extract using the same and manufacturing method therof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170092158A KR101962291B1 (en) | 2017-07-20 | 2017-07-20 | Novel Lactobacillus plantarum K118 with Antioxidant and GABA-producing ability, composition comprising a fermented product of Dendropanax morbifera extract using the same and manufacturing method therof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20190010036A true KR20190010036A (en) | 2019-01-30 |
KR101962291B1 KR101962291B1 (en) | 2019-03-26 |
Family
ID=65276879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170092158A KR101962291B1 (en) | 2017-07-20 | 2017-07-20 | Novel Lactobacillus plantarum K118 with Antioxidant and GABA-producing ability, composition comprising a fermented product of Dendropanax morbifera extract using the same and manufacturing method therof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101962291B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111004752A (en) * | 2019-12-30 | 2020-04-14 | 江南大学 | Ethanol-resistant lactobacillus plantarum and application thereof in fermented food |
CN112358987A (en) * | 2020-11-10 | 2021-02-12 | 广西壮族自治区农业科学院 | Lactobacillus plantarum strain LDVS005 and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140051543A (en) * | 2012-10-23 | 2014-05-02 | 계명대학교 산학협력단 | Method for producing fermented herb extract with high gaba content using lactobacillus plantarum k154 |
KR101423433B1 (en) | 2013-09-16 | 2014-08-13 | 전라남도 | Compositions for anti-inflammatory or prevention or treatment of food poisoning comprising extracts of fermented Dendropanax morbifera |
KR20170006797A (en) * | 2015-07-09 | 2017-01-18 | 재단법인 전남생물산업진흥원 | Composition preventing or treating andropause comprising dendropanax morbifera lev. fermentated extract |
-
2017
- 2017-07-20 KR KR1020170092158A patent/KR101962291B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140051543A (en) * | 2012-10-23 | 2014-05-02 | 계명대학교 산학협력단 | Method for producing fermented herb extract with high gaba content using lactobacillus plantarum k154 |
KR101423433B1 (en) | 2013-09-16 | 2014-08-13 | 전라남도 | Compositions for anti-inflammatory or prevention or treatment of food poisoning comprising extracts of fermented Dendropanax morbifera |
KR20170006797A (en) * | 2015-07-09 | 2017-01-18 | 재단법인 전남생물산업진흥원 | Composition preventing or treating andropause comprising dendropanax morbifera lev. fermentated extract |
Non-Patent Citations (2)
Title |
---|
Food Sci. Biotechnol., vol.23, no.6, p.1951-1957 (2014.12.31.)* * |
Kor. J. Pharmacogn., Vol.47, pp.18∼23(2016.)* * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111004752A (en) * | 2019-12-30 | 2020-04-14 | 江南大学 | Ethanol-resistant lactobacillus plantarum and application thereof in fermented food |
CN111004752B (en) * | 2019-12-30 | 2021-11-05 | 江南大学 | Ethanol-resistant lactobacillus plantarum and application thereof in fermented food |
CN112358987A (en) * | 2020-11-10 | 2021-02-12 | 广西壮族自治区农业科学院 | Lactobacillus plantarum strain LDVS005 and application thereof |
CN112358987B (en) * | 2020-11-10 | 2022-09-23 | 广西壮族自治区农业科学院 | Lactobacillus plantarum strain LDVS005 and application thereof |
Also Published As
Publication number | Publication date |
---|---|
KR101962291B1 (en) | 2019-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5162212B2 (en) | Novel lactic acid bacteria, lactic acid bacteria composition and plant extract, and method for producing plant extract and low molecular weight polyphenol | |
KR101832387B1 (en) | Method for producing fermented korean cultivated wild ginseng with enhanced specific ginsenoside content using lactic acid bacteria | |
KR20080110397A (en) | Novel lactic acid bacteria having acid resistance, bile-salt resistance and anti-bacterial effect and composition containing the same | |
KR102032703B1 (en) | Method for producing aronia fermentation product using Lactobacillus plantarum MIFI-SY3 strain | |
KR101960352B1 (en) | Lactobacillus brevis SBB07 strain from fermented berry having antimicrobial activity against pathogenic microorganism, antibiotic resistance activity, antioxidant activity, enzyme secretion activity, acid resistance activity, bile resistance activity, heat resistance activity, prebiotics substrate availability and not producing biogenic amine and uses thereof | |
KR20090083505A (en) | A method for preparing fermented ginseng of ginseng extract using lactobacillus fermentum bljh101 | |
KR101834231B1 (en) | Vegetable Lactobacillus plantarum DSR KF15 having Activities on Antimicrobial And Antifungal for keeping freshness and Use Thereof | |
KR101962291B1 (en) | Novel Lactobacillus plantarum K118 with Antioxidant and GABA-producing ability, composition comprising a fermented product of Dendropanax morbifera extract using the same and manufacturing method therof | |
KR20200054864A (en) | Complex-fermented composition of Fabaton soybean leaves and Schisandra chinensis having enhanced anti-diabetic and anti-obesity effects and preparation method thereof | |
KR20230154400A (en) | Lactobacillus plantarum hom3201 strain and its live bacterial preparation, preparation method and application | |
KR101562653B1 (en) | Bacillus subtilis CS135 strain and preparation method of Chounggukjang containing Momordica charantia using the same | |
KR101285681B1 (en) | Saponin-biotransforming activity and processes for preparing fermented ginseng using the same | |
KR20110136230A (en) | Bacillus subtilis csy191 strain and probiotics containing the strain | |
KR101960189B1 (en) | NOVEL STRAIN OF Lactobacillus plantarum AND USE THEREOF | |
KR101980450B1 (en) | Composition of active wild-cultivated ginseng having increased ginsenoside Rd and compound K, chlorgenic acid and quercetin, and preparation method thereof | |
KR101962294B1 (en) | Novel Lactobacillus plantarum K105 with Antioxidant and GABA-producing ability, composition comprising a fermented product of Dendropanax Morbifera extract using the same and manufacturing method therof | |
Nguyen et al. | Evaluation of the glucuronic acid production and other biological activities of fermented sweeten-black tea by kombucha layer and the co-culture with different Lactobacillus sp. strains | |
KR20130107940A (en) | Method of producing fermented red ginseng | |
KR102097509B1 (en) | Novel lactic acid bacteria and method of preparing fermented product having effect of anti-obesity and anti-diabets using the same | |
KR20210062367A (en) | Fermented composition comprising Angelica gigas extract and novel Lactobacillus plantarum KC23 with probiotic activities | |
KR20200067075A (en) | Fermented product of Protaetia brevitarsis extract, its preparation method and use | |
KR102606626B1 (en) | Manufacturing methods of heat-killed strain powder oriented from phellinus linteus, heat-killed strain powder and uses thereof | |
KR102218224B1 (en) | Cosmetic composition for preventing or improving skin inflammation or skin aging comprising fermented product of Ligularia stenocephala leaf as an active ingredient | |
KR102445675B1 (en) | Novel Bacillus subtilis CMIN-4 strain and its application to ginger concentrates prepared by enzymatic hydrolysis | |
KR102221579B1 (en) | NOVEL STRAIN OF Lactobacillus buchneri AND USE THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |